Board-Certified Neurologist, Specialty TBI and Headaches

Location: Del Mar – 12264 El Camino Real #202 San Diego, CA 92130
Phone: (858) 356-0361
Questions/Referrals: intake@coastalmedicalgroupsd.com

Education

  • St. Andrews College, South Africa
    First class pass and distinction in Mathematics, • 1975
  • University of the Witwatersrand Faculty of Medicine, Johannesburg, South Africa
    Bachelor of Medicine and Surgery (MD equivalent), • 1976-1981
  • Johannesburg Hospital, South Africa, • 1981-1982
    Internship, General Surgery Resident, Internal Medicine Resident
  • No. 1 Military Hospital, South Africa • 1983-1984
    Medical Officer (Full Lieutenant), Department of internal medicine
  • Johannesburg Hospital, South Africa • 1985-1986
    Neurology Resident, Department of Neurology
  • University of Massachusetts Medical School • 1986-1989
    Neurology Resident, Department of Neurology
  • University of Massachusetts Medical School • 1989-1990
    Neurophysiology Fellow:  EEG and EMG Fellowship

Licensure

  • California Medical License Number – A47863
  • NPI number – 1164459913

Certifications

  • American Board of Psychiatry and Neurology • January 1991 to 2024
  • United Council for Neurologic Subspecialties Certification in Headache Medicine • 2008 and 2024
  • ECFMG Certification, Number 337-486-5 • 1981
  • Registered – South African Medical and Dental Council, Number 24399 • 1983
  • Registered – British Medical Council, Number 3100769 • 1985
  • FMGEMS certification, Number 337-486-5 • 1986
  • FLEX certification, Number 580421014 • 1987

Awards

  • Achievement Award in Mathematics Olympiad (nationwide mathematics competition) • 1975
  • Academic Honors at St. Andrews College, South Africa • 1975
  • Dystonia Doctor of Excellence Award • 2000
  • Margaret Treat Excellence in Ethics Award, Kaiser Permanente • 2003
  • Race Across America: Completed • 2003
  • Race Across America: First Place, Corporate Challenge Division • 2004
  • American Headache Society Member’s Choice Award for the Best paper published in Headache in 2014: see reference 44 below.

Academic Appointments

  • Neurology Instructor
    University of Massachusetts, Medical School • 1988-1989

Staff Appointments

  • Director, The Los Angeles Headache Center • March 2021 – Present
  • Director, The San Diego Headache Center • March 2021 – December 2022
  • Partner, North County Neurology Associates, The Neurology Center, San Diego CA • 2004 – 2016
  • Director, The Headache Center of Southern California • 2004 – 2021
  • Partner, The Research Center of Southern California, LLC, Oceanside, California • 2007 – 2016
  • Staff Neurologist, Kaiser Permanente, San Diego, California • 1990 – 2004
  • Partner, Southern California Permanente Medical Group, San Diego, California • May 29, 1992 – 2004
  • Chief of Service, Kaiser Permanente, Neurology, San Diego, California • 1999 – 2004

Hospital Affiliations

  • Scripps Memorial Hospital, Encinitas, California, Privileges • Current

Membership

  • American Academy of Neurology: Fellow
  • American Society of Headache: Fellow

Committee Appointments

  • Past member, Bioethics committee, Kaiser Permanente, San Diego
  • Past Chairman, Bioethics committee, Kaiser Permanente, San Diego
  • Past member, Regional Bioethics committee, Kaiser Permanente, Southern California
  • Past member, Bioethics committee, Scripps Hospital, Encinitas, CA
  • Emeritus Chair, American Headache Society Special Section: Peripheral Nerve Block & Other Interventional Procedures for Headache & Facial Pain. Founding Chair, served two terms.

Office Locations

  • Coastal Medical Group at 12264 El Camino Real #202, San Diego, CA 92130
  • The Los Angeles Headache Center at 2080 Century Park E, Los Angeles, CA 90067 and 9834 Genesee Ave #411, San Diego, CA 92037

Publications and Papers

(A)      Refereed Articles:

 

  1. Blumenfeld AM, Seilling W, Isaacson M. Chloroquine-resistant plasmodium falciparum malaria in South Western Africa.  Afr. Med J. 1984; 66: 207-208.

 

  1. Blumenfeld AM, Seilling W. Acute autonomic neuropathy with Salmonella typhi infection.  Afr. Med. J. 1987; 71: 532-533.

 

  1. Fisher M., Blumenfeld AM, Smith TW.  The importance of carotid artery plaque disruption and hemorrhage.  Neurol. 1987; 44:1086-1089.

 

  1. Chad DA, Smith TW, Blumenfeld AM, Fairchild PG.  HIV-associated myopathy: Immunocytochemical Identification of an HIV antigen (gp 41) in muscle.  Neurol. 1990; 28:579-582.

 

  1. Temlett JA., Ming A, Saling M, Fritz VU, Blumenfeld AM, Bilchik T, Becker AL, Fourie PB, Reef HE. Adjunctive therapy with Bromocriptine in Parkinson’s Disease.  Afr. Med. J. 1990; 78:680-685.

 

  1. Blumenfeld AM, Recht L, Chad DA, Griffin T, Jaeckle KA.  Co-existence of Lambert-Eaton Myasthenic Syndrome and Subacute cerebellar degeneration in a patient with neuronal antibodies: differential effects of treatment.  Neurology 1991; 41:1682-1685.

 

  1. Blumenfeld AM.  Impact of Botulinum Toxin Type A treatment on medication costs and usage in difficult to treat chronic headache.  Headache Quarterly, Current Treatment and Research, Volume XIII, 2002.

 

  1. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN.  Efficacy and safety of Modafinil (Provigil) for the treatment of fatigue in Multiple Sclerosis: a two centre phase 2 study.  J Neurol Neurosurg Psychiatry 2002; 72: 0-4.

 

  1. Blumenfeld AM.  Center of Excellence for Headache Care: Group Model at Kaiser Permanente. Headache 2003; 43: 431-450.

 

  1. Blumenfeld AM, Evans RW.  Expert Opinion-Botulinum Toxin Injection for  Headache 2003,43:682-685.

 

  1. Blumenfeld AM, Binder W, Silberstein S, Blitzer A.  Procedures for Administering Botulinum Toxin Type A for Migraine and Tension Headache.  Headache 2003, 43:884-891.

 

  1. Blumenfeld AM. Botulinum Toxin Type A as an Effective Prophylactic Treatment in Primary Headache Disorders.  Headache 2003, 43:853-860.

 

  1. Silberstein S, Blumenfeld AM, Dodick D.  Botulinum Neurotoxin for the Treatment of Migraine and other Primary Headache Disorders.  Clinics in Dermatology 2004, 22:167-175.

 

  1. Blumenfeld AM, Binder WJ., Blitzer A, Katz H.  The Emerging Role of Botulinum Toxin Type A in Headache Prevention.  Operative Techniques in Otolaryngology – Head and Neck Surgery, 2004, 15:90-96.

 

  1. Blumenfeld AM, Welch KMA.  Controversies in Headache Botulinum Toxin Type A for the treatment of Headache.  Headache 2004, 44:825-830.

 

  1. Maizels M, Blumenfeld AM., Burchette R.  A Combination of Riboflavin, Magnesium and Fever Few for Migraine Prophylaxis: A randomized trial.  Headache 2004, 44:885-890.

 

  1. Blumenfeld AM.  Clinical Approaches to Migraine Prophylaxis.  The American Journal of Managed Care, Supplement 2005, 11: S55 – S61.

 

  1. Harpole L H, Samsa G P, Matchar D B, Silberstein S D, Blumenfeld A, Jurgelski A E. Burden of illness and satisfaction with care among patients with headache seen in a primary care setting. Headache, 2005; 45:1048-1055.

 

  1. Elkind AH, O’Carroll P, Blumenfeld A, DeGryse R, Dimitrova R. BoNTA-024-026-036 Study Group. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis.
    J Pain. 2006;10: 688-96.

 

  1. Blumenfeld AM., Chippendale TJ., Schim JD. Botulinum toxin type A versus

divalproex sodium for prophylactic migraine treatment: a randomized, evaluator-masked trial. Headache Care, 2006; 3(4): 119-127.

 

  1. Blumenfeld AM., Schim JD., Chippendale TJ. Botulinum Toxin Type A and Diavalproex Sodium for Prophylactic Treatment of Episodic or Chronic Migraine. Headache, 2008; 48: 210-220.

 

  1. Matchar DB, Harpole L, Samsa GP, Jurgelski A, Lipton RB, Silberstein S, Young W, Kori S, Blumenfeld A. The Headache Management Trial: A Randomized Study of Coordinated Care. Headache, 2008; 48:1294-1310.

 

  1. Blumenfeld A, et al. Patterns of use of Peripheral Nerve Blocks and Trigger Points Injections among Headache Practitioners in the USA: Results of the American Headache Society Interventional Procedure Survey. Headache, 2010; 50: 937-942.

 

  1. Ashkenazi A, Blumenfeld A, et al. Review Article: Peripheral Nerve Blocks and Trigger Point Injections in Headache Management – A Systematic Review and Suggestions for future Research. Headache, 2010; 50: 943- 952.

 

  1. Blumenfeld A, Ashkenazi A. Editorial: Nerve Blocks, Trigger Point Injections and Headache. Headache, 2010; 50: 953-954.

 

  1. Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of Injection of OnabotulinumtoxinA for Chronic Migraine: A Safe, Well-Tolerated Paradigm Based on the PREEMPT Clinical Program. Headache 2010; 50:1406-1418.
  2. Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache 2011;51(1):21-32.
  3. Blumenfeld A, Schim J, Brower J. Pure Tension-type Headache Versus Tension-type Headache in the Migraineur. Volume 14, Issue 6 Current Pain and Headache Reports.
  4. Blumenfeld AM. Injection Procedure Record for OnabotulinumtoxinA (BOTOX®, Allergan, Inc., Irvine, CA, USA) treatment. Headache, 2011;51:189
  5. Blumenfeld A, Varon S, Wilcox TK, Buse D, Kawata AK, Manack A, Goadsby PJ, Lipton RB. Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31(3): 301-315.
  6. Payne KA, Varon SF, Kawata AK, Yeomans K, Wilcox TK, Manack A, Buse DC, Lipton RB, Goadsby PJ, Blumenfeld AB. The International Burden of Migraine Study (IBMS): Study design, methodology, and baseline cohort characteristics. 2011; 31(10): 1116-1130.
  7. Stokes ME, Becker WJ, Lipton RB, Sullivan SD, Wilcox TK, Wells L, Manack A, Proskorovsky I, Gladstone J, Buse DC, Varon S, Goadsby PJ, Blumenfeld AB. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: Results from the International Burden of Migraine Study (IBMS). Headache 2011;51(7):1058-1077.

 

  1. Blumenfeld A, Evans R. OnabotulinumtoxinA for Chronic migraine. Headache 2012;52(1):140-148.

 

  1. Blumenfeld A, Gennings C, Cady R. Pharmacological Synergy: The Next Frontier on Therapeutic Advancement for Migraine. Headache 2012; 52(4):636-647.

 

  1. Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, Varon SF, Blumenfeld AM, Katsarava Z, Pascual J, Lanteri-Minet M, Cortelli P, Martelletti P.

Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain. 2012 Jul;13(5):361-378.

 

  1. LM Bloudek, M Stokes, DC Buse, TK Wilcox, RB Lipton, PJ Goadsby, SF Varon, AM Blumenfeld, Z Katsarava, J Pascual, M Lanteri-Minet, P Cortelli, P Martelleti. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of migraine Study (IBMS). Headache May 2012; 13(5): 361-78.

 

  1. Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA, Wilcox TK, Kawata AK, Lipton RB. Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II). Headache 2013 Apr;53(4):644-55.

 

  1. Blumenfeld A, et al. Expert Consensus Recommendations for the Performance of Peripheral Nerve Blocks for Headaches – A Narrative Review. Headache 2013; Mar;53(3):437-46.

 

  1. Sanderson JC, Devine EB, Lipton RB, Bloudek LM, Varon SF, Blumenfeld AM, Goadsby PJ, Buse DC, Sullivan SD. Headache-related health resource utilisation in chronic and episodic migraine across six countries. Journal of Neurology, Neurosurgery, and Psychiatry. 2013;84(12):1309-1317.

 

  1. Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener H-C, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. Journal of Neurology, Neurosurgery, and Psychiatry. 2013;331(1):48-56.

 

  1. Blumenfeld AM, Aurora SK, Laranjo K, Papapetropoulos S. Unmet Clinical Needs in Chronic Migraine: Rationale for Study and Design of COMPEL, an Open-Label, Multicenter Study of the Long-Term Efficacy, Safety, and Tolerability of OnabotulinumtoxinA for Headache Prophylaxis in Adults With Chronic Migraine. BMJ Neurology. 2015;15(100):1-9.
  2. Blumenfeld AM, Nikolskaya G. Glossopharyngeal Neuralgia. Current Pain and Headache Reports. 2013 Jul;17(7):343.

 

  1. Ashkenazi A, Blumenfeld A. OnabotulinumtoxinA for the Treatment of Headache. Headache. 2013; Sept;53(S2):54-61.

 

  1. Robbins MS, Kuruvilla D, Blumenfeld A, et al. Trigger Point Injections for Headache Disorders: Expert Consensus Methodology and Narrative Review. Headache The Journal of Head and Face Pain. 09/2014; 54(9). DOI: 10.1111/head.12442

 

  1. Lipton R, Serrano D, Blumenfeld A, Dodick D, Aurora S, Becker W, Diener HC, Wang SJ, Vincent M, Buse D, Sanderson J, Gillard P, Varon S, Reed M. Developing and validating the ID-Chronic Migraine (ID-CM) screening tool. Journal of Pain. 2014;15(4):S24.
  2. Blumenfeld AM, Ashkenazi A, Evans R. Expert opinion: Occipital and Trigeminal Nerve Blocks for Migraine. Headache The Journal of Head and Face Pain. 04/2015; DOI: 10.1111/head.12579
  3. Lipton RB, Serrano D, Buse DC, Pavlovic JM, Blumenfeld AM, Dodick DW, Aurora SK, Becker WJ, Diener H-C, Wang S-J, Vincent MB, Hindiyeh NA, Starling AJ, Gillard PJ, Varon SF, Reed ML. Development and Validation of the Identify Chronic Migraine (ID-CM) Screening Tool. Cephalalgia. 2015;36(3):203-215.
  4. Messali A, Sanderson JC, Blumenfeld AM, Goadsby PJ, Buse DC, Varon SF, Stokes M, Lipton RB. Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-based Survey. Headache. 2016;56(2):306-322.
  5. Blumenfeld A, Silberstein S, Dodick D, Aurora S, Brin M, Binder W. Insights into the Functional Anatomy behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes. 2017;57(5):766-777.

 

  1. Hareendran A, Mannix S, Skalicky A, Bayliss M, Blumenfeld A, Buse DC, Desai PR, Ortmeier BG, Sapra S. Development and exploration of the content validity of a patient-reported outcome measure to evaluate the impact of migraine- the migraine physical function impact diary (MPFID). Health and Quality of Life Outcomes. 2017; 15:224.

 

  1. Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A. Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. The Journal of Headache and Pain. 2018. DOI: 10.1186/s10194-018-0840-8.

 

  1. Blumenfeld A, Siavoshi S. The Challenges of Cervicogenic Headache. Current Pain and Headache Reports. org/10.1007/s11916-018-0699-z.

 

  1. Blumenfeld A, Stark R, Freeman M, Orejudos A, Manack Adams A. Long-Term Study of the Efficacy and Safety of OnabotulinumtoxinA for the Prevention of Chronic Migraine: COMPEL Study. The Journal of Headache and Pain. 2018; 19(1):13

 

  1. Winner P, Blumenfeld A, Eross E, Orejudos A, Mirjah D, Manack Adams A, Brin M. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients With Chronic Migraine: Results of the COMPEL Study. Drug Safety. 2018. DOI: 10.1007/s40264-019-00824-3.

 

  1. Blumenfeld AM, Tepper SJ, Robbins LD, Manack Adams A, Buse DC, Orejudos A, Silberstein SD. Effects of OnabotulinumtoxinA Treatment for Chronic Migraine on Common Comorbidities including Depression and Anxiety. Journal of Neurology, Neurosurgery, and Psychiatry. 2018; 90:353-360.

 

  1. Kim B, Chu M, Manack Adams A, Blumenfeld A. Long-Term Safety and Efficacy of OnabotulinumtoxinA for the Prevention of Chronic Migraine In a South Korean Population: COMPEL Study. Neurology Asia. 2019; 24(2):127-137.

 

  1. Young WB, Lopez J, Rothrock JF, Orejudos A, Manack Adams A, Lipton RB, Blumenfeld A. Effects of OnabotulinumtoxinA Treatment in Patients With and Without Allodynia: Results of the COMPEL Study. The Journal of Headache and Pain. DOI: 10.1186/s10194-018-0952-1.

 

  1. Young W, Lopez J, Rothrock J, Orejudos A, Manack Adams A, Lipton R, Blumenfeld A. Effects of OnabotulinumtoxinA Treatment in Patients With and Without Daily Headache at Baseline: Results From the COMPEL Study. The Journal of Headache and Pain. DOI: 10.1186/s10194-018-0953-0.

 

  1. Rothrock J, Manack Adams A, Lipton R, Silberstein SD, Ester J, Xiang Z, Blumenfeld A. FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine. Headache 26 September 2019. org/10.1111/head.13653.

 

  1. Blumenfeld AM, et al. Pharmacology and Pharmacokinetics of Ubrogepant: A Potent, Selective Calcitonin Gene‒Related Peptide Receptor Antagonist for the Acute Treatment of Migraine. Journal of Family Practice. 2020;69(1):S1-S24.

 

  1. Blumenfeld AM, Patel AT, Turner IM, Mullin KB, Manack Adams A, Rothrock JF. Patient-Reported Outcomes From a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine. J Prim Care Community Health (2020) 11:1-11.

 

  1. Burstein R, Blumenfeld AM, Silberstein SD, Adams AM, Brin MF. Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review. Headache (2020) 60:1259-1272.
  2. Blumenfeld AM, Stevanovi DM, Ortega M, Cohen JM, Seminerio MJ, Yang R, Jiang B. No Wearing-off Effect Seen in Quarterly or Monthly Dosing of Fremanezumab: Sub-analysis of a Randomized Long-term Study. Headache 2020 Oct 4. 2431-2443.
  3. Clemow DB, Johnson KW, Hochstetler HM, Ossipov MH, Hake AM, Blumenfeld AM. Lasmiditan mechanism of action – review of a selective 5-HT 1Fagonist. J Headache Pain. 2020 Jun 10;21(1):71. DOI: 10.1186/s10194-020-01132-3.
  4. Goadsby PJ, Blumenfeld AM, Lipton RB, Dodick DW, Kalidas K, Adams A, Jakate A, Liu C, Szegedi A, and Trugman J. Time Course of Efficacy of Ubrogepant for the Acute Treatment of Migraine: Clinical Implications. Cephalalgia 2020 DOI:10.1177/0333102420970523.
  5. Blumenfeld AM, Goadsby PJ, Dodick DW, Hutchinson S, Liu C, Finnegan M, Trugman JM, Szegedi A. Efficacy of Ubrogepant Based on Prior Exposure and Response to Triptans: A Post Hoc Analysis. Headache. 2021. DOI: 10.1111/head.14089.
  6. Jakate A, Blumenfeld AM, Boinpally R, Butler M, Borbridge L, Contreras-De Lama J, McGeeney D, Periclou A, Lipton RB. Pharmacokinetics and Safety of Ubrogepant When Coadministered With CGRP-Targeted Monoclonal Antibody Migraine Preventives in Participants With Migraine: A Randomized Phase 1b Drug-Drug Interaction Study. Headache. 2021. DOI: 10.1111/head.14095.
  7. Hutchinson S, Silberstein SD, Blumenfeld AM, Lipton RB, Lu K, Yu SY, Severt L. Safety and Efficacy of Ubrogepant in Participants with Major Cardiovascular Risk Factors in 2 Single-Attack Phase 3 Randomized Trials: ACHIEVE I and II. Cephalalgia. 2021;e-Pub 4/19/21.
  8. Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L, Manack Adams A. Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to onabotulinumtoxinA: A retrospective chart review. Pain and Therapy. 2021 Dec;10(2):809-826. DOI: 10.1007/s40122-021-00264-x.Epub 2021 Apr 21.
  9. Blumenfeld A, Durham PL., Feoktistov A, Hay DL., Russo AF., Turner I. Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor Neurol Ther. org/10.1007/s40120-021-00250-7
  10. Blumenfeld, A.M., Boyd, J.P. Adjunctive treatment of chronic migraine using an oral dental device: overview and results of a randomized placebo-controlled crossover study. BMC Neurol22, 72 (2022). org/10.1186/s12883-022-02591-8
  11. Blumenfeld AM, Knievel k, Manack Adams, Lawrence S, Matthew B, Hongxin L, Dodick DW. Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials. Adv Ther. org/10.1007/s12325-021-01923-3

 

  1. Aliani J, Blumenfeld AM. Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine. Headache. DOI: 1111/head.14244.

 

  1. Blumenfeld AM. Clinican-Patient Dialogue About preventive Chronic Migraine Treatment Journal of Primary Care and Community Health 2020-01. DOI: 1177/2150132720959935.

 

  1. Ailani J, Kuruppu DK, Rettiganti M, Oakes T, Schroeder K, Wietecha L, Port M, Blumenfeld AM. Does “wearing off” of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials. Headache org/10.1111/head.14257

 

76. Andrew Blumenfeld, Aud Nome Dueland, Stefan Evers, Bronwyn Jenkins, Paolo Martelletti, Katherine Sommer. Practical Insights on       the Identification and Management of Patients with Chronic Migraine  Pain and Therapy: doi.org/10.1007/s40122-022-00387-9.

 

  1. Andrew Blumenfeld, Jennifer McVige, Kerry Knievel. Post-traumatic headache: Pathophysiology and management- A review. Journal of Concussion. Volume 6: 1-10. DOI 10.1177/20597002221093478.

 

  1. Richard B Lipton, Patricia Pozo-Rosich, Andrew M Blumenfeld, David Dodick, peter Mc Allister, Ye li, Kaifeng Lu, Brett Dabruzzo, Rosa Miceli, Lawrence Severt, Michelle Finnegan, Joel M Trugman. Rates of Response to Atogepant for Migraine Prophylaxis Among Adults. A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open.2022;5(6):e2215499. DOI:10.1001/jamanetworkopen.2022.15499.

 

  1. Richard B. Lipton, Patricia Pozo-Rosich, Andrew Blumenfeld, Ye Li, Lawrence Severt, Jonathan T Stokes, Lela Creutz, Pranav Gandhi, and David W. Dodick. Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial. NEUROLOGY MS ID#: NEUROLOGY/2021/177058.

 

  1. Christopher Gottschalk, Andrew Blumenfeld, et al. The Importance of an Early Onset of Migraine Preventive Disease Control: A Roundtable Discussion. Cephalalgia Reports. REP-00025-RE-2022.R1.

 

  1. Andrew M Blumenfeld, Gavneet Kaur, Anadi Mahajan, Hemlata Shukla, Katherine Sommer, and Kerry L Knievel. Effectiveness and safety of chronic migraine preventive treatments: a systematic literature review. Pain and Therapy PATH-D-22-00191R1.

 

  1. Rigmor H. Jensen, Henrik Winther Schytz, Cristina Tassorelli, Gisela M. Terwindt, Louise N. Carlsen, Aurélia Mittoux, Ole Østerberg, Richard B. Lipton, Stewart J. Tepper, Andrew Blumenfeld, Christofer Lundqvist. Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: protocol for RESOLUTION – a phase 4, multi-national, randomised, double-blind, placebo-controlled study. F Neurol., 22 February 2023. Sec. Headache and Neurogenic Pain. Volume 14.

 

  1. David Dodick, Andrew Blumenfeld, Rashmi Halker Singh, Rachel Williams, Feng Zhang, Po-wei Chen, Cheng-Pang Hsu, Cheng Peng, Jossefin Snellman, Mahan Chehrenama, Jessica Aliani. Post hoc Analysis of clinical trial data and pharmacokinetic data to assess wearing-off of Erenumab within monthly treatment cycle. Headache 2022: 00: 1-10.

 

  1. Blumenfeld, A. Ettrup, J. Hirman, B. Ebert, R. Cady. Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with Eptinezumab. BMC Neurology 2022; 22:251.

 

  1. Tepper, A Blumenfeld. Remote Electrical Neuromodulation (REN) for migraine prevention: a double-blind randomized placebo-controlled clinical trial
    Accepted Headache: The Journal of Head and Face Pain. Article ID: HEAD14469.

 

  1. A Blumenfeld, et al. Phase 1b, Open-label, Fixed-sequence, Drug-Drug Interaction, Safety, and Tolerability Study Between Atogepant and Ubrogepant in Participants with a History of Migraine. Headache: The Journal of Head and Face Pain. org/10.1111/head.14433.

 

  1. M Ashina, S Tepper, U Reuter, A Blumenfeld, S Hutchinson, J Xia, R Miceli, L Severt, M Finnegan, J Trugman. Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial. 18 January 2023. Headache: The Journal of Head and Face Pain. org/10.1111/head.14439.

 

  1. M Boczarska-Jedynak, A Blumenfeld. Injection technique of the upper face with onabotulinumtoxinA in chronic migraine 27 June 2023. Headache: The Journal of Head and Face Pain. org/10.1111/head.14588.

 

  1. Schwedt T, Lee J, Knieel K, McVige J, Wang W, Wu Z, Gillard P, Shah D, Blumenfeld AM. Real-World Persistence and Costs Among Patients With Chronic Migraine Treated With OnabotulinumtoxinA or CGRP Monoclonal Antibodies. J Manag Care Spec Pharm. 2023 jmcp.org/doi/abs/10.18553/jmcp.2023.29.10.1119

 

  1. A Blumenfeld, S Tepper, R Khanna, E Doty, M Vincent, S Miller. Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience. Front. Neurol., 27 October 2023. Sec. Headache and Neurogenic Pain Volume 14 – 2023 https:/doi.org/10.3389/fneur.2023 1291102.

 

  1. Blumenfeld, A.M.; Edvinsson, L.; Jakate, A.; Banerjee, P. Pharmacology and Pharmacokinetics of Ubrogepant: A Potent, Selective Calcitonin Gene-Related Peptide Receptor Antagonist for the Acute Treatment of Migraine.
  2. Fam. Pract. 2020, 69 (Suppl. 1), S8–S12.

 

  1. Blumenfeld A, Kudrow D, McAllister P, Boserup LP, Hirman J, Cady R. Long-term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication-overuse headache. Headache. 2024; 00: 1-12. doi:1111/head.14767
  2. B. Lipton, J. Ailani, K. Mullin, J.M. Pavlovic, S.J. Tepper, D.W. Dodick, A.M. Blumenfeld. Situational prevention: Pharmacotherapy during periods of increased risk for migraine attacks. Headache. 2024;00:1–6. DOI: 10.1111/head.14775

 

(B)       Journal Letters:

 

  1. Fisher M, Blumenfeld AM, Smith TW. Carotid Plaque Disruption.  Neurol. 1989; 46:605.

 

  1. Fisher M, Lingley JF, Blumenfeld AM, Felice K.  Anterior choroidal artery territory infarction and small vessel disease.  Stroke 1989; 20:1591-1592.

 

  1. Blumenfeld A. Does single-file Botox injection really work for primary headache?
    Headache, 2004; 8: 838-9.

 

  1. Blumenfeld A, Bender SD, Glassman B, Malizia D. Bruxism, temporomandibular dysfunction, tension type headache, and migraine: a comment. Headache 2011; Nov- Dec; 51(10):1549-50.

 

  1. Blumenfeld A, et al. Pharmacological Synergy: The Next Frontier on Therapeutic Advancement for Migraine. Headache 2012; 52(10): 1600-1601.

 

  1. Blumenfeld AM. Clinician-Patient Dialogue About Preventive Chronic Migraine

Treatment. J Prim Care Community Health 2020;11:1-6.

 

  1. Blumenfeld AM, Silberstein S. Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic Migraine in Clinical Practice. Headache 2020. Page 2589.

 

  1. Ailani J, Blumenfeld AM. Combination CGRP Monoclonal Antibody and OnabotulinumtoxinA Treatment for Preventive Treatment in Chronic Migraine. Headache.

 

 

(C)      Chapters and Reviews:

 

  1. Phillips C, Blumenfeld AM. Status Epilepticus.  Intensive Care Medicine, Second Edition, 1991, 1565-1569.

 

  1. Blumenfeld AM. Botulinum Toxin in Primary Headache Disorders. Medlink  2003 -2013.

 

(D)      Guidelines:

 

  1. Blumenfeld AM, Blalock E, Kazimiroff P, Van Petten C, Ratcliffe J. Headache Guidelines. Clinical Practice Guidelines, Kaiser Permanente 1996.

 

  1. Blumenfeld AM. Headache Guidelines. Clinical Practices Guidelines, Kaiser Permanente 2003.

 

(E)      Books:

 

Rapoport A, Sheftell F, Tepper S J, Blumenfeld AM. Conquering Daily Headache 2008 Decker DTC.

 

 

(F)      Posters:

 

  1. Blumenfeld A. Chronic daily headache treated non-pharmaceutically with Nociceptive Trigeminal Inhibition Dental Splint. Presented at the International Headache Society, London September 2008.Aurora S, Schim J, Cutrer FM, Ward TN, Blumenfeld AB, Lay C, Patel S, Lei X, Turkel CC. Botulinum neurotoxin type A for treatment of chronic migraine: PREEMPT 1 trial double-blind phase. Presented at the 14th International Headache Congress (IHC), September 10-13, 2009, Philadelphia, Pennsylvania; PO45.

 

  1. Buse D, Lipton RB, Kawata AK, Varon SF, Manack A, Wilcox TK, Goadsby PJ, Blumenfeld A. Global impact of chronic migraine (CM) compared to episodic migraine (EM) on health-related quality of life (HRQoL), depression and anxiety. Presented at the 14th International Headache Congress (IHC), September 10-13, 2009, Philadelphia, Pennsylvania.
  2. Blumenfeld A, Tarzemany R, Neshandar M, Jalalian E, Beladimoghaddam N. Combination therapy: Valproic Acid with an NTI clenching reduction dental splint for prophylactic treatment of primary Headache: a pilot study for efficacy assessment. Presented at the 14th International Headache Congress (IHC), September 10-13, 2009, Philadelphia, Pennsylvania.
  3. Payne KA, Wilcox TK, Yeomans K, Kawata AK, Varon SF, Burk CT, Lipton RB, Blumenfeld A. Clinical history, resource utilization, and other patient-reported outcomes (PROs) in migraineurs: An adaptable web-based methodology for the design, implementation and conduct of a multinational survey of patients. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual International Meeting, May 16-20, 2009, Orlando, Florida.
  4. Payne KA, Wilcox TK, Yeomans K, Kawata AK, Varon SF, Burk CT, Lipton RB, Blumenfeld A. Clinical history, resource utilization, and other patient-reported outcomes (PROs) in migraineurs: An adaptable web-based methodology for the design, implementation and conduct of a multinational survey of patients. Presented at the 12th European International Society for Pharmacoeconomics and Outcomes Research Congress (ISPOR EU), October 24-27, 2009, Paris, France.
  5. Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Sirimanne M, DeGryse R, Turkel CC. OnabotulinumtoxinA for treatment of chronic migraine: Analysis of the PREEMPT chronic migraine subgroup who were overusing acute headache medications at baseline. Presented at the 14th International Headache Congress (IHC), September 10-13, 2009, Philadelphia, Pennsylvania; PO49.
  6. Varon SF, Blumenfeld A, Lipton RB, Manack A, Buse D, Wilcox TK, Goadsby PJ, Kawata AK. Health care resource utilization patterns among individuals with chronic migraine (CM) and episodic migraine (EM). Presented at the 14th International Headache Congress (IHC), September 10-13, 2009, Philadelphia, Pennsylvania, PO126.
  7. Varon SF, Burk CT, Buse DC, Kawata AK, Payne KA, Blumenfeld A, Lipton RB. Impact of chronic (CM) and episodic migraine (EM) on work presenteeism in 9 countries. Presented at the 12th European International Society for Pharmacoeconomics and Outcomes Research Congress (ISPOR EU), October 24-27, 2009, Paris, France.
  8. Varon SF, Burk CT, Buse DC, Kawata AK, Payne KA, Blumenfeld A, Lipton RB. Impact of chronic (CM) and episodic migraine (EM) on work presenteeism in 9 countries. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual International Meeting, May 16-20, 2009, Orlando, Florida.
  9. Aurora SK, Dodick DW, Blumenfeld AM, DeGryse RE, Turkel CC. OnabotulinumtoxinA for Chronic Migraine: Safety and Tolerability of the Effective Treatment Paradigm in the PREEMPT Clinical Program. Presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS), June 24-27, 2010, Los Angeles, California; PO-27.
  10. Blumenfeld AM, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. OnabotulinumtoxinA for chronic migraine: PREEMPT clinical program establishes a safe and effective dose and injection paradigm. Presented at the 62nd Annual Meeting of the American Academy of Neurology (AAN), April 10-17, 2010, Toronto, ON, Canada.
  11. Blumenfeld AM, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. OnabotulinumtoxinA for chronic migraine: PREEMPT trials establish a safe and effective dose and injection paradigm. Presented at the 2nd European Headache and Migraine Trust International Congress (EHMTIC 2010), October 28-31, 2010, Nice, France.
  12. Becker WJ, Kawata AK, Yeomans K, Varon SF, Lipton RB, Wells L, Blumenfeld AM. Headache severity, comorbidities, and healthcare resource utilization (RU) among chronic migraine (CM) and episodic migraine (EM) in Canada. Presented at the Canadian Neurological Sciences Federation (CNSF) 45th Annual Congress, June 8-11, 2010, Quebec City, Canada.
  13. Becker WJ, Wilcox TK, Wells L, Blumenfeld AM, Kawata AK, Varon SF, Lipton RB. Migraine-related disability, work impact, and quality of life (QOL) among Canadians with chronic migraine (CM) and episodic migraine (EM). Presented at the Canadian Neurological Sciences Federation (CNSF) 45th Annual Congress, June 8-11, 2010, Quebec City, Canada.
  14. Blumenfeld AM, Kawata TK, Goadsby PJ, Buse DC, Wilcox TK, Varon SF, Lipton RB. Preventive medication use among Americans with chronic and episodic migraine. Presented at the American Managed Care Pharmacy (AMCP) 2010 Educational Conference, October 13-15, 2010, St. Louis, Missouri.
  15. Blumenfeld AM, Lipton RB, Buse DC, Kawata AK, Wilcox TK, Varon SF, Goadsby PJ. Impact on chronic and episodic migraine on work patterns in five European countries. Presented at the 2nd European Headache and Migraine Trust International Congress (EHMTIC 2010), October 28-31, 2010, Nice, France.
  16. Cortelli P, Martelleti P, Stokes M, Varon SF, Sullivan SD, Blumenfeld AM, Buse DC, Lipton RB, Wilcox TK, Goadsby PJ. Healthcare resource use and costs among chronic and episodic migraine in Italy. Presented at the XLI Congresso Societa Italiana di Neurologia (SIN), 2010.
  17. Cortelli P, Martelletti P, Lipton RB, Blumenfeld A, Kawata AK, Varon SF, Renoldi M, Goadsby PJ. Impact of chronic versus episodic migraine on disability, health-related quality of life in Italy. Presented at the Italian Internal Medicine Congress (SIMI), 2010.
  18. Cortelli P, Martelletti P, Lipton RB, Blumenfeld A, Kawata AK, Varon SF, Renoldi M, Goadsby PJ. Impact of chronic versus episodic migraine on disability and health-related quality of life in Italy (Impatto dell’emicraina cronica respetto all’emicranica episodica sulla disabitlà di vita in Italia. Presented at the IV Congresso Nazionale Association Neurologica Italiana per la Riserca sulle Cefalee (ANIRCEF), June 2, 2010, Genoa, Italy.
  19. Cortelli P, Martelletti P, Lipton RB, Blumenfeld A, Kawata AK, Varon SF, Renoldi M, Goadsby PJ. Impact of chronic versus episodic migraine on disability, health-related quality of life in Italy. Presented at the XLI Congresso Societa Italiana di Neurologia (SIN), 2010.
  20. Cortelli P, Martelletti P, Stokes M, Varon SF, Sullivan S, Blumenfeld A, Buse DC, Lipton RB, Wilcox TK, Goadsby PJ. Healthcare resource use and costs among chronic and episodic migraine in Italy. Presented at the Italian Internal Medicine Congress (SIMI), 2010.
  21. Goadsby PJ, Lipton RB, Varon SF, Buse DC, Kawata AK, Wilcox TK, Blumenfeld A, Girod I. Impact of chronic versus episodic migraine on disability, health-related quality of life (HRQoL) and resource utilization in the UK. Presented at the Association of British Neurologists (ABN) Annual Meeting, May 11-14, 2010, Bournemouth, UK; POH02.
  22. Katsarava Z, Blumenfeld A, Wilcox TK, Voelkel H, Varon SF, Buse DC, Lipton RB, Goadsby PJ. Der Einfluss chronischer im Vergleich zu episodischer Migräne auf Behinderung, Gesundheits-bezogene Lebensqualität (HRQoL) und Inanspruchnahme von Gesundheitsleistungen in Deutschland. Presented at the Deutscher Schmerzkongress, 2010.
  23. Kawata AK, Maglinte GA, Doan QV, Lipton RB, Wilcox TK, Blumenfeld AM, Goadsby PJ. Comparing EuroQoL-5 Dimensions (EQ-5D) index scores between subjects with Chronic Migraine (CM) and Episodic Migraine (EM) in five European countries and with other chronic diseases. Presented at the 14th Congress of the European Federation of Neurological Societies (EFNS), September 25-28, 2010, Geneva, Switzerland.
  24. Kawata AK, Varon SF, Blumenfeld AM, Lipton RB, Wilcox TK, Goadsby PJ. Health-related quality of life among subjects with chronic migraine and episodic migraine in five European countries. Presented at the 14th Congress of the European Federation of Neurological Societies (EFNS), September 25-28, 2010, Geneva, Switzerland.
  25. Lipton RB, Blumenfeld A, Ishak KJ, Varon SF, Kawata AK, Manack A, Buse DC, Goadsby PJ. Determinants of migraine-related disability. Presented at the 62nd Annual Meeting of the American Academy of Neurology (AAN), April 10-17, 2010, Toronto, ON, Canada.
  26. Lipton RB, Varon SF, Goadsby PJ, Buse DC, Kawata AK, Wilcox TK, Blumenfeld AM. Acute medication use among Americans with chronic and episodic migraine. Presented at the American Managed Care Pharmacy (AMCP) 2010 Educational Conference, October 13-15, 2010, St. Louis, Missouri.
  27. Martelletti P, Cortelli P, Lipton RB, Blumenfeld AM, Kawata AK, Varon SF, Renoldi M, Goadsby PJ. Healthcare resource use and costs among chronic and episodic migraine in Italy. Presented at the XXIV Congresso Nazionale Societa Sientica Multidisciplinare Dedicata alla Cefalee (SISC), 2010.
  28. Martelletti P, Cortelli P, Lipton RB, Blumenfeld AM, Kawata AK, Varon SF, Renoldi M, Goadsby PJ. Impact of chronic versus episodic migraine on disability and health-related quality of life in Italy. Presented at the XXIV Congresso Nazionale Societa Sientica Multidisciplinare Dedicata alla Cefalee (SISC), 2010.
  29. Stokes M, Varon SF, Blumenfeld AM, Buse DC, Lipton RB, Wilcox TK, Goadsby PJ. Health resources uses and costs among chronic and episodic migraine in five european countries. Presented at the 2nd European Headache and Migraine Trust International Congress (EHMTIC 2010), October 28-31, 2010, Nice, France.
  30. Blumenfeld A. Adverse events related to the NTI splint: report from the Headache Hope study. Presented at the 2nd European Headache and Migraine Trust International Congress (EHMTIC 2010), October 28-31, 2010, Nice, France.
  31. Stokes M, Varon SF, Sullivan SD, Blumenfeld AM, Lipton RB, Goadsby PJ, Wilcox TK. Healthcare resource use and costs among chronic and episodic migraine in the United States. Presented at the American Managed Care Pharmacy (AMCP) 2010 Educational Conference, October 13-15, 2010, St. Louis, Missouri.
  32. Wilcox TK, Blumenfeld A, Varon S, Payne K, Manack A, Buse D, Goadsby P, Lipton R. Relationship between headache frequency and migraine-related disability in the International Burden of Migraine Study (IBMS). Presented at the 62nd Annual Meeting of the American Academy of Neurology (AAN), April 10-17, 2010, Toronto, ON, Canada.
  33. Becker WJ, Buse DC, Lipton RB, Bloudek LM, Maglinte GA, Varon SF, Wilcox TK, Kawata AK, Blumenfeld AM. Discontinuation of preventive treatment for episodic migraine (EM) and chronic migraine (CM): Results from the International Burden of Migraine Study-II (IBMS-II). Presented at 15th Congress of the International Headache Society (IHC), June 23-26, 2011, Berlin, Germany.
  34. Blumenfeld AM, Buse DC, Becker WJ, Wilcox TK, Kawata AK, Bloudek LM, Maglinte GA, Varon SF, Lipton RB. Sociodemographics and headache-related disability among persons with episodic migraine or chronic migraine by preventive medication use status: Results from the International Burden of Migraine Study-II (IBMS-II). Presented at 15th Congress of the International Headache Society (IHC), June 23-26, 2011, Berlin, Germany.
  35. Blumenfeld AM, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. OnabotulinumtoxinA for chronic migraine: PREEMPT clinical program establishes a safe and effective dose and injection paradigm. Presented at the 22nd Annual Meeting of the American Academy of Pain Management (AAPM), September 20-23, 2011, Las Vegas, Nevada.
  36. Blumenfeld AM, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. OnabotulinumtoxinA for chronic migraine: PREEMPT trials establish a safe and effective dose and injection paradigm. Presented at the 7th International Congress on Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins (TOXINS 2011), October 2-5, Santa Fe, New Mexico.
  37. Evans C, Aurora S, Fitzgerald K, Varon S, Bloudeck L, Banderas B, Blumenfeld A. Development of new patient-reported outcome measures in chronic migraine. Presented at the 63rd American Academy of Neurology (AAN) 2011 Annual Meeting, April 9-16, 2011, Honolulu, Hawaii.
  38. Lipton RB, Bloudek LM, Blumenfeld AM, Buse DC, Wilcox TK, Kawata AK, Maglinte GA, Varon SF, Becker WJ. Use of preventive medications for episodic migraine and chronic migraine: Results from the International Burden of Migraine Study-II (IBMS-II). Presented at 15th Congress of the International Headache Society (IHC), June 23-26, 2011, Berlin, Germany.
  39. Maglinte GA, Bloudek LM, Stokes ME, Wells L, Blumenfeld AM, Lipton RB, Buse DC, Becker WJ, Wilcox TK. Costs associated with lost productive time among working adults with chronic and episodic migraine in the United States and Canada. Presented at 63rd American Academy of Neurology (AAN) 2011 Annual Meeting, April 9-16, 2011, Honolulu, Hawaii.
  40. Maglinte GA, Bloudek LM, Stokes ME, Wells L, Blumenfeld AM, Lipton RB, Buse DC, Becker WJ, Wilcox TK. Costs associated with lost productive time among working adults with chronic and episodic migraine in the United States and Canada. Presented at the 22nd Annual Meeting of the American Academy of Pain Management (AAPM), September 20-23, 2011, Las Vegas, Nevada.
  41. Maglinte GA, Bloudek LM, Stokes ME, Wells L, Blumenfeld AM, Lipton RB, Buse DC, Becker WJ, Wilcox TK. Costs associated with lost productive time among working adults with chronic and episodic migraine in the United States and Canada. Presented at the Headache Update of the Diamond Headache Clinic Research and Educational Foundation (DHCREF), July 14-17, 2011, Lake Buena Vista, Florida.
  42. Stokes ME, Varon SF, Sullivan S, Blumenfeld AM, Lipton RB, Goadsby PJ, Wilcox TK. Healthcare resource use and costs among patients with chronic and episodic migraine in the United States. Presented at 63rd American Academy of Neurology (AAN) 2011 Annual Meeting, April 9-16, 2011, Honolulu, Hawaii; P06.016.
  43. Stokes ME, Varon SF, Sullivan S, Blumenfeld AM, Lipton RB, Goadsby PJ, Wilcox TK. Healthcare resource use and costs among patients with chronic and episodic migraine in the United States. Presented at the Headache Update of the Diamond Headache Clinic Research and Educational Foundation (DCHREF), July 14-17, 2011, Lake Buena Vista, Florida.
  44. Stokes ME, Varon SF, Sullivan S, Blumenfeld AM, Lipton RB, Goadsby PJ, Wilcox TK. Healthcare resource use and costs among patients with chronic and episodic migraine in the United States. Presented at the 22nd Annual Meeting of the American Academy of Pain Management (AAPM), September 20-23, 2011, Las Vegas, Neva
  45. Blumenfeld AM, Aurora SL, Laranjo K, Papapetropoulos S. Rationale for study and design of COMPEL: An open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine. Presented at the 54th Annual Meeting of the American Headache Society (AHS), June 21-24, 2012, Los Angeles, CA.
  46. Blumenfeld AM, Inocelda A, Purdy C, Dalfonso L, Magar R. The durability of onabotulinumtoxinA for the treatment of chronic migraine: CLARITY pilot study. Presented at the 66th Annual Meeting of the American Academy of Neurology (AAN), April 26-May 3, 2014, Philadelphia, PA.
  47. Blumenfeld AM, Inocelda A, Purdy C, Dalfonso L, Magar R. Long-term treatment of chronic migraine with onabotulinumtoxinA: CLARITY pilot study. Presented at the 33rd Annual Meeting of the American Pain Society (APS), April 30-May 3, 2014, Tampa, FL.
  48. Blumenfeld AM, Inocelda A, Purdy C, Dalfonso L, Magar R. The durability of onabotulinumtoxinA for the treatment of chronic migraine: CLARITY pilot study. Presented at the Headache Update of the Diamond Headache Clinic Research and Educational Foundation (DHCREF), July 17-20, 2014, Lake Buena Vista, FL.
  49. Blumenfeld AM, Inocelda A, Purdy C, Dalfonso L, Magar R. The durability of onabotulinumtoxinA for the treatment of chronic migraine: CLARITY pilot study. Presented at PAINweek, September 2-6, 2014, Las Vegas, NV.
  50. Lipton RB, Serrano D, Blumenfeld AM, Dodick D, Aurora S, Becker W, Diener H-C, Wang S-J, Vincent M, Buse D, Sanderson J, Varon S, Reed M. Developing and validating the ID-Chronic Migraine (ID-CM) screening tool. Presented at the 66th Annual Meeting of the American Academy of Neurology (AAN), April 26-May 3, 2014, Philadelphia, PA.
  51. Lipton RB, Serrano D, Blumenfeld A, Dodick D, Aurora S, Becker W, Diener H-C, Wang S-J, Vincent M, Buse D, Sanderson J, Gillard P, Varon S, Reed M. Developing and validating the ID-Chronic Migraine (ID-CM) screening tool. Presented at the 33rd Annual Meeting of the American Pain Society (APS), April 30-May 3, 2014, Tampa, FL.
  52. Lipton RB, Serrano D, Blumenfeld AM, Dodick D, Aurora S, Becker W, Diener H-C, Wang S-J, Vincent M, Buse D, Sanderson J, Gillard P, Varon S, Reed M. Developing and validating the ID-Chronic Migraine (ID-CM) screening tool. Presented at the National Conference of the American Association of Nurse Practitioners (AANP), June 17-22, 2014, Nashville, TN.
  53. Lipton RB, Serrano D, Buse D, Blumenfeld AM, Dodick D, Aurora S, Becker W, Diener H-C, Wang S-J, Vincent M, Pavlovic J, Sanderson J, Varon S, Gillard P, Reed M. Development and validation of a screening tool for chronic migraine (ID-CM). Presented at the 56th Annual Meeting of the American Headache Society (AHS), June 26-29, 2014, Los Angeles, CA.
  54. Lipton RB, Serrano D, Buse D, Pavlovic J, Blumenfeld AM, Dodick D, Aurora S, Becker W, Diener H-C, Wang S-J, Vincent M, Yang M, Varon S, Reed M, Gillard P. Development and validation of a screening tool for chronic migraine (ID-CM). Presented at the Headache Update of the Diamond Headache Clinic Research and Educational Foundation (DHCREF), July 17-20, 2014, Lake Buena Vista, FL.
  55. Rosa K, Evans C, Lai H, Yang M, Gillard P, Aurora S, Blumenfeld AM. Psychometric evaluation of the Assessment of Chronic Migraine Impacts (ACM-I) and Assessment of Chronic Migraine Symptoms (ACM-S). Presented at the 56th Annual Meeting of the American Headache Society (AHS), June 26-29, 2014, Los Angeles, CA.
  56. Aurora S, Blumenfeld AM, Stark R, Reppine A, Manack Adams A. Descriptive comparison of the efficacy and safety of onabotulinumtoxinA for headache prophylaxis in adult chronic migraine patients from two long-term, multicenter studies: COMPEL vs. PREEMPT. Presented at the 17th International Congress of the International Headache Society (IHS), May 14-17, Valencia, Spain.
  57. Aurora S, Blumenfeld AM, Stark R, Reppine A, Manack Adams A. Descriptive comparison of the efficacy and safety of onabotulinumtoxinA for headache prophylaxis in adult chronic migraine patients from two long-term, multicenter studies: COMPEL vs. PREEMPT. Presented at the 57th Annual Meeting of the American Headache Society (AHS), June 18-21, 2015, Washington, DC.
  58. Blumenfeld AM, Inocelda A, Purdy C, Dalfonso L, Magar R. The durability of onabotulinumtoxinA for the treatment of chronic migraine: CLARITY pilot study. Presented at the 2nd Conference on Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins of the International Neurotoxin Association (INA TOXINS), January 14-17, 2015, Lisbon, Portugal.
  59. Blumenfeld AM, Stark R, Reppine A, Halstead M, Holdbrook F, Aurora S. Efficacy and safety of onabotulinumtoxinA in a long-term, open-label study for the prophylaxis of headaches in adult chronic migraine patients: an interim analysis of the COMPEL study. Presented at the 67th Annual Meeting of the American Academy of Neurology (AAN), April 18-25, 2015, Washington, DC.
  60. Blumenfeld AM, Stark R, Reppine A, Halstead M, Holdbrook F, Manack Adams A, Aurora S. Efficacy and safety of onabotulinumtoxinA for the prophylaxis of headaches in adult chronic migraine patients: an interim analysis of the long-term, multicenter, open-label study, COMPEL. Presented at the 34th Annual Meeting of the American Pain Society (APS), May 13-16, 2015, Palm Springs, CA.
  61. Blumenfeld AM, Stark R, Reppine A, Manack Adams A, Aurora S. Efficacy and safety of onabotulinumtoxinA for the prophylaxis of headaches in adult chronic migraine patients: an interim analysis of the prospective, long-term, multicenter, open-label study: COMPEL. Presented at the Headache Update of the Diamond Headache Clinic Research and Educational Foundation (DHCREF), July 16-19, Lake Buena Vista, FL.
  62. Cady R, Blumenfeld AM, Chappell P, Jo E, Manack Adams A. Efficacy, safety, and tolerability of onabotulinumtoxinA versus topiramate for chronic migraine headache prophylaxis in a prospective, randomized, open-label study: FORWARD study methods. Presented at the 17th International Congress of the International Headache Society (IHS), May 14-17, Valencia, Spain.
  63. Cady R, Blumenfeld A, Chappell P, Jo E, Manack Adams. Efficacy, safety, and tolerability of onabotulinumtoxinA versus topiramate for chronic migraine headache prophylaxis in a prospective, randomized, open-label study: FORWARD study methods. Presented at the Headache Update of the Diamond Headache Clinic Research and Educational Foundation (DHCREF), July 16-19, Lake Buena Vista, FL.
  64. Blumenfeld A, Stark R, Manack Adams A, Orejudos A, Aurora S. Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL. European Headache and Migraine Trust International Congress 2016. 2016; September 15-18, Glasgow, UK.
  65. Kim BK, Chu MK, Orejudos A, Manack Adams A, Blumenfeld A. Safety and Efficacy of OnabotulinumtoxinA in the Korean Population: Data from Open-Label 108-Week COMPEL Study. Asian Regional Congress for Headache – 6th. 2016; October 15-16, Seoul, Korea.
  66. Blumenfeld A, Stark R, Manack Adams A, Orejudos A, Aurora S. Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL. International Neurotoxin Association – 3rd Conference (TOXINS 2017). 2017; January 18-21, Madrid, Spain.
  67. Blumenfeld A, Stark R, Manack Adams A, Orejudos A, Aurora S. Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL . American Academy of Neurology 2017 – 69th Annual Meeting. 2017;88(16 Supplement P2):178, Los Angeles, CA.
  68. Blumenfeld A, Tepper S, Robbins L, Manack Adams A, Silberstein S. The Effects of OnabotulinumtoxinA Treatment on the Chronic Migraine Comorbidities of Sleep and Fatigue. American Headache Society – 59th Annual Scientific Meeting. 2017;57(Supp S3):142-143; San Francisco, CA.
  69. Lopez J, Blumenfeld A, Young W, Manack Adams A, Rothrock J. Effects of OnabotulinumtoxinA Treatment on Disability and Quality of Life in Patients with Chronic Migraine with Baseline Headache Every Day: A COMPEL Subanalysis. American Headache Society – 59th Annual Scientific Meeting. 2017;57(Supp S3):167-168,San Francisco, CA.
  70. Young W, Rothrock J, Lopez J, Manack Adams A, Blumenfeld A. Effects of OnabotulinumtoxinA Treatment on Disability and Quality of Life in Patients with Chronic Migraine with Baseline Allodynia: A COMPEL Subanalysis. American Headache Society – 59th Annual Scientific Meeting. 2017;57(Supp S3):171-172. San Francisco, CA.
  71. Blumenfeld A, Tepper S, Robbins L, Manack Adams A, Silberstein S. Effects of OnabotulinumtoxinA Treatment on Chronic Migraine Comorbidities of Sleep and Fatigue. European Academy of Neurology – 3rd Congress. 2017;24(Supp 1):163; Lisbon, Portugal.
  72. Young W, Rothrock J, Lopez J, Manack Adams A, Blumenfeld A. Effects of OnabotulinumtoxinA Treatment on Disability and Quality of Life in Patients with Chronic Migraine with Baseline Headache Every Day or Allodynia: A COMPEL Subanalysis . European Academy of Neurology – 3rd Congress. 2017;24(Supp 1):712; Lisbon, Portugal.
  73. Blumenfeld A, Tepper S, Robbins L, Manack Adams A, Silberstein S. The Effects of OnabotulinumtoxinA Treatment on the Chronic Migraine Comorbidities of Sleep and Fatigue. Headache Update 2017.
  74. Blumenfeld A, Stark R, Manack Adams A, Orejudos A, Aurora S. Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL . Headache Update 2017.
  75. Blumenfeld A, Patel A, Manack Adams A, Rothrock J. A Multicenter, Prospective, Randomized, Open-Label Study To Compare OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults with Chronic Migraine: Patient-Reported Outcomes From The FORWARD Study. Headache Update 2018. 2018.
  76. Blumenfeld A, Patel A, Manack Adams A, Rothrock J. A Multicenter, Prospective, Randomized, Open-Label Study to Compare the OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults with Chronic Migraine: Patient Reported Functional Outcomes From The FORWARD Study. European Headache Federation – 12th European Headache Federation Congress. 2018; Florence, Italy.
  77. Blumenfeld A, Tepper S, Robbins L, Manack Adams A, Buse D, Silberstein S. Effects of OnabotulinumtoxinA Treatment on Chronic Migraine Comorbidities of Depression and Anxiety: Psychiatric Comorbidities Responder Analysis. American Academy of Neurology 2018 – 70th Annual Meeting. 2018; Los Angeles, CA.
  78. Blumenfeld A, Tepper S, Robbins L, Manack Adams A, Buse D, Silberstein S. Effects of OnabotulinumtoxinA Treatment on Chronic Migraine Comorbidities of Depression and Anxiety: Psychiatric Comorbidities Responder Analysis. Practicing Physician’s Approach to the Difficult Headache Patient – 31st Annual. 2018.
  79. Blumenfeld A, Tepper S, Robbins L, Manack Adams A, Buse D, Silberstein S. The Effects of OnabotulinumtoxinA Treatment on the Chronic Migraine Comorbidities of Sleep and Fatigue. American Academy of Neurology 2018 – 70th Annual Meeting. 2018; Los Angeles, CA.
  80. Blumenfeld A, Tepper S, Robbins L, Orejudos A, Manack Adams A, Buse D, Silberstein S. Effect of OnabotulinumtoxinA Prevention on Comorbidities of Depression and Anxiety in Chronic Migraine: Analysis in Headache Day Frequency Responders vs Headache Day Frequency Non-Responders. American Headache Society – 60th Annual Scientific Meeting. 2018; San Francisco, CA.
  81. Blumenfeld A, Tepper S, Robbins L, Orejudos A, Manack Adams A, Buse D, Silberstein S. Effect of OnabotulinumtoxinA Prevention on Comorbidities of Depression and Anxiety in Chronic Migraine: Analysis in Headache Day Frequency Responders vs Headache Day Frequency Non-Responders. European Academy of Neurology – 4th Congress. 2018; Lisbon, Portugal.
  82. Blumenfeld A, Tepper S, Robbins L, Orejudos A, Manack Adams A, Buse D, Silberstein S. Effect of OnabotulinumtoxinA Prevention on Comorbidities of Depression and Anxiety in Chronic Migraine: Analysis in Headache Day Frequency Responders vs Headache Day Frequency Non-Responders. Headache Update 2018. 2018.
  83. Blumenfeld AM, Patel AT, Manack Adams A, Rothrock JF. A Multicenter, Prospective, Randomized, Open-Label Study to Compare OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine: Patient-Reported Functional Outcomes From the FORWARD Study. Migraine Trust International Symposium – 17th Biennial. 2018; London, England.
  84. Blumenfeld AM, Tepper SJ, Robbins LD, Orejudos AC, Manack Adams A, Buse DC, Silberstein SD. Effect of OnabotulinumtoxinA Prevention on Comorbidities of Depression and Anxiety in Chronic Migraine: Analysis in Headache Day Frequency Responders vs Headache Day Frequency Non-Responders. European Headache Federation – 12th European Headache Federation Congress. 2018; Florence, Italy.
  85. Blumenfeld AM, Tepper SJ, Robbins LD, Orejudos AC, Manack Adams A, Buse DC, Silberstein SD. Effect of OnabotulinumtoxinA Prevention on Comorbidities of Depression and Anxiety in Chronic Migraine: Analysis in Headache Day Frequency Responders vs Headache Day Frequency Nonresponders. Migraine Trust International Symposium – 17th Biennial. 2018; London, England.
  86. Brin M, Winner P, Blumenfeld A, Eross E, Orejudos A, Manack Adams A. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients: COMPEL Analysis by Treatment Cycle. Practicing Physician’s Approach to the Difficult Headache Patient – 31st Annual. 2018.
  87. Lopez J, Blumenfeld A, Young W, Manack Adams A, Lipton R, Rothrock J. Effects of OnabotulinumtoxinA Treatment on Disability and Quality of Life in Patients with Chronic Migraine with Baseline Daily Headache: A COMPEL Subanalysis. American Academy of Neurology 2018 – 70th Annual Meeting. 2018; Los Angeles, CA.
  88. Lopez JI, Blumenfeld AM, Young WB, Manack Adams A, Lipton RB, Rothrock JF. Effects of OnabotulinumtoxinA Treatment on Headache Frequency, Intensity, and Impact in Patients With or Without Daily Headache at Baseline: A COMPEL Subanalysis. Migraine Trust International Symposium – 17th Biennial. 2018; London, England.
  89. Rothrock J, Lipton R, Silberstein S, Jo E, Zhao X, Manack Adams A, Blumenfeld A. A Multicenter, Prospective, Randomized, Open-Label Study To Compare the Efficacy, Safety, and Tolerability of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine: The FORWARD Study. Headache Update 2018. 2018.
  90. Rothrock J, Lipton R, Silberstein S, Manack Adams A, Jo E, Zhao X, Blumenfeld A . A Multicenter, Prospective, Randomized, Open-Label Study to Compare the Efficacy, Safety, and Tolerability of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine: The FORWARD Study. American Headache Society – 60th Annual Scientific Meeting. 2018; San Francisco, CA.
  91. Rothrock J, Lipton R, Silberstein S, Manack Adams A, Jo E, Zhao X, Blumenfeld A. A Multicenter, Prospective, Randomized, Open-label Study to Compare the Efficacy, Safety, and Tolerability of OnabotulinumtoxinA and Topiramate for Headache Prophylaxis in Adults with Chronic Migraine: The FORWARD Study. American Academy of Neurology 2018 – 70th Annual Meeting. 2018; Los Angeles,CA.
  92. Rothrock J, Manack Adams A, Jo E, Zhao X, Blumenfeld A. A Multicenter, Prospective, Randomized, Open-Label Study to Compare the Efficacy, Safety, and Tolerability of OnabotulinumtoxinA and Topiramate for Headache Prophylaxis in Adults with Chronic Migraine: The FORWARD Study. Practicing Physician’s Approach to the Difficult Headache Patient – 31st Annual. 2018.
  93. Tepper S, Wilson M, Orejudos A, Manack Adams A, Blumenfeld A. The Long-Term Efficacy and Safety of OnabotulinumtoxinA for the Prevention of Chronic Migraine in Patients with Medication Overuse: Results of the COMPEL Study. American Headache Society – 60th Annual Scientific Meeting. 2018; San Francisco, CA.
  94. Tepper S, Wilson M, Orejudos A, Manack Adams A, Blumenfeld A. The Long-Term Efficacy and Safety of OnabotulinumtoxinA for the Prevention of Chronic Migraine in Patients With Medication Overuse: Results of the COMPEL Study. Headache Update 2018. 2018.
  95. Tepper SJ, Wilson MC, Rothrock JF, Orejudos A, Manack Adams A, Blumenfeld AM. Effect of OnabotulinumtoxinA on the Frequency and Impact of Headaches in Patients with Chronic Migraine with or without a History of Acute Pain Medication Overuse: Results of the COMPEL Study. European Headache Federation – 12th European Headache Federation Congress. 2018; Florence, Italy.
  96. Tepper SJ, Wilson MC, Rothrock JF, Orejudos AC, Manack Adams A, Blumenfeld AM. Effect of OnabotulinumtoxinA on the Frequency and Impact of Headaches in Patients With Chronic Migraine With or Without a History of Acute Pain Medication Overuse: Results of the COMPEL Study. Migraine Trust International Symposium – 17th Biennial. 2018; London, England.
  97. Winner P, Blumenfeld A, Eross E, Orejudos A, Manack Adams A, Brin M. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients: COMPEL Analysis by Treatment Cycle. American Academy of Neurology 2018 – 70th Annual Meeting. 2018; Los Angeles, CA.
  98. Winner P, Blumenfeld A, Eross E, Orejudos A, Manack Adams A, Brin M. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients: COMPEL Analysis by Treatment Cycle. American Headache Society – 60th Annual Scientific Meeting. 2018; San Francisco, CA.
  99. Winner PK, Blumenfeld AM, Eross EJ, Orejudos AC, Manack Adams A, Brin MF. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients Taking Oral Preventive Medications: COMPEL Analysis by Treatment Cycle. Migraine Trust International Symposium – 17th Biennial. 2018; London, England.
  100. Young W, Rothrock J, Lopez J, Manack Adams A, Lipton R, Blumenfeld A. Effects of OnabotulinumtoxinA Treatment on Headache Frequency, Disability and Quality of Life in Patients with Chronic Migraine with Baseline Allodynia: A COMPEL Subanalysis. American Academy of Neurology 2018- 70th Annual Meeting. 2018; Los Angeles, CA.
  101. Young WB, Rothrock JF, Lopez JI, Manack Adams A, Lipton RB, Blumenfeld AM. Effects of OnabotulinumtoxinA on Headache Frequency and Impact in Patients With Chronic Migraine With or Without Baseline Allodynia: A COMPEL Subanalysis. Migraine Trust International Symposium – 17th Biennial. 2018; London, England.
  102. Rothrock JF, Lipton RB, Young WB, Jo E, Manack Adams A, Blumenfeld AM. OnabotulinumtoxinA Is Safe and Effective in Patients Who Discontinue Topiramate: Results of the FORWARD Study. American Academy of Neurology – 71st Annual Meeting. 2019; Philadelphia, PA.
  103. Blumenfeld AM, Goadsby PJ, Dodick DW, Hutchinson S, Liu C, Finnegan M, Trugman JM, Szegedi A. Ubrogepant Is Effective for the Acute Treatment of Migraine in Patients With an Insufficient Response to Triptans. American Academy of Neurology – 71st Annual Meeting. 2019; Philadelphia, PA.
  104. Ailani J, Blumenfeld AM, Klein B, Finnegan M, Severt L, Liu CC, Trugman JM. An Optional Second Dose of Ubrogepant is Effective in Achieving 2-Hour Pain Freedom in the Acute Treatment of Migraine. American Headache Society – 61st Annual Scientific Meeting. 2019; Philadelphia, PA.
  105. Rothrock JF, Stark R, Sommer K, Blumenfeld AM. Healthcare Resource Utilization in Adult Patients Treated With OnabotulinumtoxinA for Chronic Migraine: Results From the COMPEL Study. American Headache Society – 61st Annual Scientific Meeting. 2019; Philadelphia, PA.
  106. Rothrock JF, Lipton RB, Young WB, Jo E, Manack Adams A, Blumenfeld AM. OnabotulinumtoxinA Is Safe and Effective in Patients Who Discontinue Topiramate: Results of the FORWARD Study. American Headache Society – 61st Annual Scientific Meeting. 2019; Philadelphia, PA.
  107. Hutchinson S, Silberstein SD, Blumenfeld AM, Lipton RB, Lu K, Yu SY, Severt L. Safety and Efficacy of Ubrogepant in Participants With Moderate to High Cardiovascular Risk. American Headache Society – 61st Annual Scientific Meeting. 2019; Philadelphia, PA.
  108. Rothrock JF, Lipton RB, Young WB, Jo E, Manack Adams A, Blumenfeld AM. OnabotulinumtoxinA Is Safe and Effective in Patients Who Discontinue Topiramate: Results of the FORWARD Study. Academy of Managed Care Pharmacy – 31st Annual Meeting & Expo. 2019; National Harbor, MD.
  109. Blumenfeld AM, Goadsby PJ, Dodick DW, Hutchinson S, Liu C, Finnegan M, Trugman JM, Szegedi A. Ubrogepant is Effective for the Acute Treatment of Migraine in Patients for Whom Triptans are Ineffective. Academy of Managed Care Pharmacy – 31st Annual Meeting & Expo. 2019; National Harbor, MD.
  110. Rothrock JF, Manack Adams A, Lipton RB, Silberstein SD, Jo E, Zhao X, Blumenfeld AM. Multicenter, Prospective, Randomized, Open-Label Study Comparing Efficacy, Safety, and Tolerability of OnabotulinumtoxinA and Topiramate in Chronic Migraine: The FORWARD Study. Canadian Pain Society – 40th Annual Conference. 2019; Toronto, ON.
  111. Rothrock JF, Lipton RB, Young WB, Jo E, Manack Adams A, Blumenfeld AM. OnabotulinumtoxinA Is Safe and Effective in Patients Who Discontinue Topiramate: Results of the FORWARD Study. Headache Update. 2019; Lake Buena Vista, FL.
  112. Blumenfeld AM, Dodick DW, Hutchinson S, Liu C, Finnegan M, Trugman JM, Szegedi A. Ubrogepant Is Effective For the Acute Treatment of Migraine in Patients with an Insufficient Reponse to Triptans. Headache Update. 2019; Lake Buena Vista, FL.
  113. Blumenfeld AM, Patel AT, Manack Adams A, Rothrock JF. OnabotulinumtoxinA Treatment Associated With Greater Tolerability and Improved Patient-Reported Functional Outcomes Than Topiramate: Results from the FORWARD Study. 32nd Annual Practicing Physician’s Approach to the Difficult Headache Patient. 2019; Carlsbad, CA.
  114. Rothrock JF, Lipton RB, Young WB, Jo E, Manack Adams A, Blumenfeld AM. OnabotulinumtoxinA Is Safe and Effective in Patients Who Discontinue Topiramate: Results of the FORWARD Study. European Academy of Neurology – 5th Congress. 2019; Olso, Norway.
  115. Rothrock JF, Stark R, Sommer K, Blumenfeld AM. Healthcare Resource Utilization in Adult Patients Treated With OnabotulinumtoxinA for Chronic Migraine: Results From the COMPEL Study. European Headache Federation – 13th European Headache Federation Congress. 2019; Athens, Greece.
  116. Winner PK, Blumenfeld AM, Eross EJ, Orejudos A, Manack Adams A, Brin MF. OnabotulinumtoxinA Is Well Tolerated In Chronic Migraine Patients Taking Oral Preventive Medications: Long-Term Compel Analysis By Treatment Cycle. The International Neurotoxin Association’s 4th international conference – TOXINS 2019: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins. 2019; Copenhagen, Denmark.
  117. Blumenfeld AM, Tepper SJ, Robbins LD, Orejudos AC, Manack Adams A, Buse DC, Silberstein SD. OnabotulinumtoxinA Treatment For Chronic Migraine Reduces Depression And Anxiety In Headache Day Frequency Responders And Nonresponders. The International Neurotoxin Association’s 4th international conference – TOXINS 2019: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins. 2019; Copenhagen, Denmark.
  118. Hutchinson S, Silberstein SD, Blumenfeld AM, Lipton RB, Lu K, Yu SY, Severt L. Safety and Efficacy of Ubrogepant in Participants With Moderate to High Cardiovascular Risk. Headache Cooperative of the Pacific – 13th Annual Winter Conference. 2020; Ojai, CA.
  119. Blumenfeld AM, Goadsby PJ, Dodick DW, Hutchinson S, Liu C, Finnegan M, Trugman JM, Szegedi A. Ubrogepant is Effective for the Acute Treatment of Migraine in Patients with an Insufficient Response to Triptans. Headache Cooperative of the Pacific – 13th Annual Winter Conference. 2020; Ojai, CA.
  120. Hutchinson S, Silberstein SD, Blumenfeld AM, Lipton RB, Lu K, Yu SY, Severt L. Safety and Efficacy of Ubrogepant in Participants With Moderate to High Cardiovascular Risk. Diamond Headache Clinic Research and Educational Foundation – Annual Research Summit. 2020; San Diego, CA.
  121. Blumenfeld AM, Diener HC, Lipton RB, Dodick DW, Degryse R, Manack Adams A, Silberstein SD. Clinically Meaningful Benefits of OnabotulinumtoxinA Beyond Headache Days in Chronic Migraine: Analysis of the COMPEL and Pooled PREEMPT Studies. Diamond Headache Clinic Research and Educational Foundation – Annual Research Summit. 2020; San Diego, CA.
  122. Ailani J, Blumenfeld AM, Klein B, Finnegan M, Severt L, Liu CC, Trugman JM. An Optional Second Dose of Ubrogepant is Effective in Achieving 2-Hour Pain Freedom in the Acute Treatment of Migraine. American Academy of Neurology 2020 – 72nd Annual Meeting. 2020; Virtual.
  123. Blumenfeld AM, Knievel K, Manack Adams A, Severt L, Butler M, Lai J, Dodick DW. Efficacy and Safety of Ubrogepant in Participants Taking Concomitant Preventive Medication. American Academy of Neurology 2020 – 72nd Annual Meeting. 2020; Virtual.
  124. Blumenfeld AM, Yedigarova L, Lipton RB. Benefits of Long-Term OnabotulinumtoxinA Treatment in Chronic Migraine: Results from the COMPEL Study. American Academy of Neurology 2020 – 72nd Annual Meeting. 2020; Virtual.
  125. Rothrock JF, Luo L, Eross EJ, Sommer K, Blumenfeld AM. Responder Rates to OnabotulinumtoxinA in Patients With Chronic Migraine: A Post Hoc Analysis of the COMPEL Study. American Academy of Neurology 2020 – 72nd Annual Meeting. 2020; Virtual.
  126. Blumenfeld AM, Diener HC, Lipton RB, Dodick DW, Degryse R, Manack Adams A, Silberstein SD. Clinically Meaningful Benefits of OnabotulinumtoxinA Beyond Headache Days in Chronic Migraine: Analysis of the COMPEL and Pooled PREEMPT Studies. American Academy of Neurology 2020 – 72nd Annual Meeting. 2020; Virtual.
  127. Rothrock JF, Stark R, Sommer K, Blumenfeld AM. Healthcare Resource Utilization in Adult Patients Treated With OnabotulinumtoxinA for Chronic Migraine: Results From the COMPEL Study. American Academy of Neurology 2020 – 72nd Annual Meeting. 2020; Virtual.
  128. Severt L, Silberstein SD, Blumenfeld AM, Lipton RB, Lu K, Yu SY, Hutchinson S. Safety and Efficacy of Ubrogepant in Participants With Moderate to High Cardiovascular Risk. American Academy of Neurology 2020 – 72nd Annual Meeting. 2020; Virtual.
  129. Jakate A, Blumenfeld AM, Boinpally R, Butler M, Borbridge L, Contreras-De Lama J, McGeeney D, Periclou A, Lipton RB. Pharmacokinetics, Safety, and Tolerability of Ubrogepant for the Acute Treatment of Migraine Following Coadministration With Preventive Monoclonal Antibody Treatment. American Headache Society – 62nd Annual Scientific Meeting. 2020; Virtual.
  130. Blumenfeld AM, Luo L, Yedigarova L, Lipton RB. Benefits of Long-Term OnabotulinumtoxinA Treatment in Chronic Migraine: Results from the COMPEL Study. American Headache Society – 62nd Annual Scientific Meeting. 2020; Virtual.
  131. Rothrock JF, Luo L, Eross E, Sommer K, Blumenfeld AM. Responder Rates to OnabotulinumtoxinA in Patients With Chronic Migraine: A Post Hoc Analysis of the COMPEL Study. American Headache Society – 62nd Annual Scientific Meeting. 2020; Virtual.
  132. Blumenfeld AM, Knievel K, Manack Adams A, Severt L, Butler M, Lai H, Dodick DW. Efficacy and Safety of Ubrogepant in Participants Taking Concomitant Preventive Medication. American Headache Society – 62nd Annual Scientific Meeting. 2020; Virtual.
  133. Blumenfeld AM, Luo L, Yedigarova L, Lipton RB. Benefits of Long-Term OnabotulinumtoxinA Treatment in Chronic Migraine: Results from the COMPEL Study. EHF (2020) European Headache Federation – 14th European Headache Federation Congress. 2020; Virtual.
  134. Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L, Manack Adams A. Real-World Evidence for Control of Patients With Chronic Migraine Who Received CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment. MTIS (2020) Migraine Trust International Symposium – 2020 Virtual Symposium.
  135. Jakate A, Blumenfeld AM, Boinpally R, Butler M, Borbridge L, Contreras-De Lama J, McGeeney D, Periclou A, Lipton RB. Pharmacokinetics, Safety, and Tolerability of Ubrogepant for the Acute Treatment of Migraine Following Coadministration With Preventive Monoclonal Antibody Treatment. MTIS (2020) Migraine Trust International Symposium – 2020 Virtual Symposium.
  136. Blumenfeld AM, Knievel K, Manack Adams A, Severt L, Butler M, Lai H, Dodick DW. Efficacy and Safety of Ubrogepant in Participants Taking Concomitant Preventive Medication. MTIS (2020) Migraine Trust International Symposium – 2020 Virtual Symposium.
  137. Blumenfeld AM, Diener HC, Lipton RB, Dodick DW, Degryse R, Manack Adams A, Sommer K, Silberstein SD. Clinically Meaningful Benefits of OnabotulinumtoxinA Beyond Headache Days in Chronic Migraine: Analysis of the COMPEL and Pooled PREEMPT Studies. ABN (2020) Association of British Neurologists – 2020 Annual Meeting.
  138. Blumenfeld AM, Knievel K, Manack Adams A, Severt L, Butler M, Lai H, Dodick DW. Efficacy and Safety of Ubrogepant in Participants Taking Concomitant Preventive Medication. HCOP (2021) Headache Cooperative of the Pacific – 14th Annual Winter Conference; Virtual.
  139. Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Yedigarova L, Manack Adams A. Real-World Evidence for Control of Patients With Chronic Migraine Who Received CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment. HCOP (2021) Headache Cooperative of the Pacific – 14th Annual Winter Conference; Virtual.
  140. Blumenfeld AM, Frishberg BM, Schim JD, Hughes O, Manack Adams A. Real-World Evidence for Control of Chronic Migraine in Patients Meeting American Headache Society Criteria Who Received Calcitonin Gene‒Related Peptide Monoclonal Antibody Therapy Added to OnabotulinumtoxinA. DHCREF (2021) Diamond Headache Clinic Research and Educational Foundation – 2021 Annual Research Summit; Virtual.
  141. Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes J, Gandhi P, Dodick DW. Effects of Atogepant as Evaluated by the Activity Impairment in Migraine-Diary (AIM-D) and Headache Impact Test (HIT-6) in a 12-Week, Double-blind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine. AMCP (2021) Academy of Managed Care Pharmacy 2021 – 33rd Annual Meeting & Expo; Virtual.
  142. Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes J, Gandhi P, Dodick DW. Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine. AMCP (2021) Academy of Managed Care Pharmacy 2021 – 33rd Annual Meeting & Expo; Virtual.
  143. Blumenfeld AM, Frishberg BM, Schim JD, Hughes O, Yedigarova L, Manack Adams A. Real-World Evidence for Control of Patients With Chronic Migraine Who Received Calcitonin Gene‒Related Peptide (CGRP) Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment. AMCP (2021) Academy of Managed Care Pharmacy 2021 – 33rd Annual Meeting & Expo; Virtual.
  144. Jakate A, Blumenfeld AM, Boinpally R, Butler M, Borbridge L, Contreras-De Lama J, McGeeney D, Periclou A, Lipton RB. Pharmacokinetics, Safety, and Tolerability of Ubrogepant for the Acute Treatment of Migraine Following Coadministration With Preventive Monoclonal Antibody Treatment. AAN (2021) American Academy of Neurology 2021 – 73rd Annual Meeting; Virtual.
  145. Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes J, Gandhi P, Dodick DW. Atogepant Improved Patient-Reported Outcome (PRO) Measures of Activity Impairment in Migraine-Diary and Headache Impact Test in a 12-Week, Doubleblind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine. AAN (2021) American Academy of Neurology 2021 – 73rd Annual Meeting; Virtual.
  146. Dodick DW, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes J, Gandhi P, Lipton RB. Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine. AAN (2021) American Academy of Neurology 2021 – 73rd Annual Meeting; Virtual.
  147. Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Yedigarova L, Manack Adams A. Real-World Evidence for Control of Chronic Migraine (CM) in Patients Meeting American Headache Society (AHS) Criteria Who Received Calcitonin Gene‒Related Peptide Monoclonal Antibody (CGRPmAb) Therapy Added to OnabotulinumtoxinA Treatment. AAN (2021) American Academy of Neurology 2021 – 73rd Annual Meeting; Virtual.
  148. Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Yedigarova L, Manack Adams A. Real-World Evidence for Control of Patients With Chronic Migraine Who Received Calcitonin Gene‒Related Peptide (CGRP) Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment. AAN (2021) American Academy of Neurology 2021 – 73rd Annual Meeting; Virtual.
  149. Lipton RB, Pozo Rosich P, Blumenfeld AM, Dodick DW, McAllister, Li Y, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman JM. Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days. AHS (2021) American Headache Society – 63rd Annual Scientific Meeting; Virtual.
  150. Ashina M, Tepper SJ, Reuter U, Blumenfeld AM, Hutchinson S, Xia J, Miceli R, Severt L, Finnegan M, Trugman JM. Atogepant 60 mg Once Daily Shows Efficacy for the Preventive Treatment of Migraine: Results From a 52-Week Open-label Extension Trial. AHS (2021) American Headache Society – 63rd Annual Scientific Meeting; Virtual.
  151. Blumenfeld AM, Frishberg BM, Schim JD, Hughes O, Yedigarova L, Manack Adams A. Real-World Evidence for Control of Chronic Migraine (CM) in Patients Meeting American Headache Society (AHS) Criteria Who Received Calcitonin Gene‒Related Peptide Monoclonal Antibody (CGRPmAb) Therapy Added to OnabotulinumtoxinA Treatment. AHS (2021) American Headache Society – 63rd Annual Scientific Meeting; Virtual.
  152. Ashina M, Tepper A, Reuter U, Blumenfeld A, Hutchinson S, Xia J, Miceli R, Severt L, Finnegan M, Trugman J. Long-term Safety and Tolerability of Atogepant Following Once-Daily Dosing Over 1 Year for the Preventive Treatment of Migraine. AHS (2021) American Headache Society – 63rd Annual Scientific Meeting; Virtual.
  153. Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes J, Gandhi P, Dodick DW. Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine. AHS (2021) American Headache Society – 63rd Annual Scientific Meeting; Virtual.
  154. Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes J, Gandhi P, Dodick DW. Effects of Atogepant as Evaluated by the Activity Impairment in Migraine-Diary (AIM-D) and Headache Impact Test (HIT-6) in a 12-Week, Double-blind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine. AHS (2021) American Headache Society – 63rd Annual Scientific Meeting; Virtual.
  155. Ashina M, Tepper S, Reuter U, Blumenfeld A, Hutchinson S, Xia J, Miceli R, Severt L, Finnegan M, Trugman J. Atogepant 60 mg Once-Daily Shows Efficacy for the Preventive Treatment of Migraine: Results From a 52-Week Open-Label Extension Trial. AANP (2021) American Association of Nurse Practitioners – 2021 National Conference; Virtual.
  156. Lipton RB, Pozo Rosich P, Blumenfeld AM, Dodick D, McAllister, Li Y, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman J . Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days. AANP (2021) American Association of Nurse Practitioners – 2021 National Conference; Virtual.
  157. Blumenfeld AM, Frishberg BM, Schim JD, Hughes O, Sommer K, Manack Adams A. Real-World Evidence for Chronic Migraine Control in Patients Receiving Treatment With CGRP mAbs and OnabotulinumtoxinA. AANP (2021) American Association of Nurse Practitioners – 2021 National Conference; Virtual.
  158. Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes J, Gandhi P, Dodick DW. Atogepant Improved Patient Functioning Using MSQ v2.1 in a 12-Week Phase 3 (ADVANCE) Trial for Migraine Prevention. EAN (2021) European Academy of Neurology – 7th Congress; Virtual.
  159. Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes J, Gandhi P, Dodick DW. Atogepant improved patient-reported outcome (PRO) measures of activity impairment in migraine-diary and Headache Impact Test in a 12-week, double-blind, randomized phase 3 (ADVANCE) trial for preventive treatment of migraine. DHCREF (2021) Headache Update 2021.
  160. Lipton RB, Pozo Rosich P, Blumenfeld AM, Dodick DW, McAllister, Li Y, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman JM. Daily Atogepant for the preventive treatment of migraine increases responder rates for reduction in mean monthly migraine days. DHCREF (2021) Headache Update 2021.
  161. Ashina M, Tepper SJ, Reuter U, Blumenfeld AM, Hutchinson S, Xia J, Miceli R, Severt L, Finnegan M, Trugman JM. Atogepant 60 mg once-daily shows efficacy for the preventive treatment of migraine: results from a 52-week open-label extension trial. DHCREF (2021) Headache Update 2021.
  162. Ashina M, Tepper S, Reuter U, Blumenfeld A, Hutchinson S, Xia J, Miceli R, Severt L, Finnegan M, Trugman J. Long-term safety and tolerability of Atogepant 60 mg following once-daily dosing over 1 year for the preventive treatment of migraine. DHCREF (2021) Headache Update 2021.
  163. Blumenfeld AM, Frishberg BM, Schim JD, Hughes O, Manack Adams A. Real-world evidence for control of patients with chronic migraine who received CGRP monoclonal antibody therapy added to OnabotulinumtoxinA treatment. DHCREF (2021) Headache Update 2021.
  164. Blumenfeld AM, Frishberg BM, Schim JD, Hughes O, Manack Adams A. Real-World Evidence for Control of Patients With Chronic Migraine Who Received Calcitonin Gene-Related Peptide Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment. EHF (2021) European Headache Federation – 15th European Headache Federation Congress; Virtual.
  165. Lipton RB, Pozo Rosich P, Blumenfeld AM, Dodick D, McAllister, Li Y, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman J. Oral Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days. EHF (2021) European Headache Federation – 15th European Headache Federation Congress; Virtual.
  166. Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes J, Gandhi P, Dodick DW. Effects of Atogepant as Evaluated by the Activity Impairment in Migraine-Diary (AIM-D) and Headache Impact Test (HIT-6) in a 12-Week, Double-blind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine. EHF (2021) European Headache Federation – 15th European Headache Federation Congress; Virtual.
  167. Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes J, Gandhi P, Dodick DW. Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine. EHF (2021) European Headache Federation – 15th European Headache Federation Congress; Virtual.
  168. Lipton RB, Pozo Rosich P, Blumenfeld AM, Dodick D, McAllister, Li Y, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman J. Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days. PAINWeek (2021) PAIN Week 2021; Virtual.
  169. Ashina M, Tepper S, Reuter U, Blumenfeld A, Hutchinson S, Xia J, Miceli R, Severt L, Finnegan M, Trugman J. Atogepant 60 mg Once-Daily Shows Efficacy for the Preventive Treatment of Migraine: Results From a 52-Week Open-Label Extension Trial. PAINWeek (2021) PAIN Week 2021; Virtual.
  170. Lipton RB, Pozo Rosich P, Blumenfeld AM, Dodick D, McAllister, Li Y, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman J. Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days. AMCP (2021) Academy of Managed Care Pharmacy – 9th Nexus Conference.
  171. Ashina M, Tepper SJ, Reuter U, Blumenfeld AM, Hutchinson S, Xia J, Miceli R, Severt L, Finnegan M, Trugman JM. Atogepant 60 mg Once Daily Shows Efficacy for the Preventive Treatment of Migraine: Results From a 52-Week Open-label Extension Trial. AMCP (2021) Academy of Managed Care Pharmacy – 9th Nexus Conference.

(G) Presentations

  1. Blumenfeld A, Patel A, Zhao X, Manack Adams A, Rothrock J. A Multicenter, Prospective, Randomized, Open-Label Study to Compare the OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults with Chronic Migraine: Patient Reported Outcomes From The FORWARD Study. American Headache Society – 60th Annual Scientific Meeting. 2018; San Francisco, CA.
  2. Pascual J, Blumenfeld A, Tepper S, Robbins L, Orejudos A, Manack Adams A, Buse D, Silberstein S . Effect of OnabotulinumtoxinA in Depression and Anxiety Associated With Chronic Migraine. Sociedad Espanola de Neurologia – LXX Reunion Anual. 2018; Seville, Spain.
  3. Rothrock J, Lipton R, Silberstein S, Jo E, Zhao X, Manack Adams A, Blumenfeld A. A Multicenter, Prospective, Randomized, Open-Label Study to Compare the Efficacy, Safety, and Tolerability of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults with Chronic Migraine: The FORWARD Study. European Academy of Neurology – 4th Congress. 2018; Lisbon, Portugal.
  4. Rothrock J, Tepper S, Wilson M, Orejudos A, Manack Adams A, Blumenfeld A. The Long-Term Efficacy and Safety of OnabotulinumtoxinA for the Prevention of Chronic Migraine in Patients with Medication Overuse: Results of the COMPEL Study. European Academy of Neurology – 4th Congress. 2018; Lisbon, Portugal.

 

  1. Blumenfeld AM, Goadsby PJ, Dodick DW, Hutchinson S, Liu C, Finnegan M, Trugman JM, Szegedi A. Ubrogepant is Effective for the Acute Treatment of Migraine in Patients for Whom Triptans are Ineffective. American Headache Society – 61st Annual Scientific Meeting. 2019; Philadelphia, PA.

 

  1. Blumenfeld AM, Tepper SJ, Robbins LD, Orejudos A, Adams AM, Buse DC, Silberstein SD. Effect of OnabotulinumtoxinA Prevention on Comorbidities of Depression and Anxiety in Chronic Migraine: Analysis in Headache Day Frequency Responders vs Headache Day Frequency Non-Responders. The International Neurotoxin Association’s 4th international conference – TOXINS 2019: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins. 2019; Copenhagen, Denmark.

 

  1. Rothrock JF, Stark R, Sommer K, Blumenfeld AM. Healthcare Resource Utilization in Adult Patients Treated With OnabotulinumtoxinA for Chronic Migraine: Results From the COMPEL Study. American Academy of Neurology 2020 – 72nd Annual Meeting. 2020; Virtual.

 

  1. Blumenfeld AM, Frishberg BM, Schim JD, Hughes O, Manack Adams A. Real-World Evidence for Control of Patients With Chronic Migraine Who Received Calcitonin Gene‒Related Peptide Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment. AHS (2021) American Headache Society – 63rd Annual Scientific Meeting; Virtual.

 

  1. Blumenfeld AM, Frishberg BM, Schim JD, Hughes O, Sommer K, Manack Adams A. Real-World Evidence for Chronic Migraine Control in Patients Receiving Treatment with CGRP mAbs and OnabotulinumtoxinA. EAN (2021) European Academy of Neurology – 7th Congress; Virtual.

 

  1. Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes J, Gandhi P, Dodick DW. Atogepant Improved Measures of Functioning Using AIM-D and HIT-6 in a 12-Week Phase 3 Trial for Migraine Prevention. EAN (2021) European Academy of Neurology – 7th Congress; Virtual.

 

 

(H) Abstracts

  1. Blumenfeld A, Patel A, Manack Adams A, Rothrock J. A Multicenter, Prospective, Randomized, Open-Label Study To Compare OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults with Chronic Migraine: Patient-Reported Outcomes From The FORWARD Study. Headache Update 2018.
  2. Blumenfeld A, Patel A, Zhao X, Manack Adams A, Rothrock J. A Multicenter, Prospective, Randomized, Open-Label Study to Compare the OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults with Chronic Migraine: Patient Reported Outcomes From The FORWARD Study. American Headache Society – 60th Annual Scientific Meeting. 2018; San Francisco, CA.
  3. Blumenfeld A, Tepper S, Robbins L, Manack Adams A, Buse D, Silberstein S. Effects of OnabotulinumtoxinA Treatment on Chronic Migraine Comorbidities of Depression and Anxiety: Psychiatric Comorbidities Responder Analysis. Practicing Physician’s Approach to the Difficult Headache Patient – 31st Annual. 2018.
  4. Blumenfeld A, Tepper S, Robbins L, Manack Adams A, Buse D, Silberstein S. Effects of OnabotulinumtoxinA Treatment on Chronic Migraine Comorbidities of Depression and Anxiety: Responder Analysis. American Academy of Neurology 2018 – 70th Annual Meeting. 2018; Los Angeles, CA.
  5. Blumenfeld A, Tepper S, Robbins L, Orejudos A, Manack Adams A, Buse D, Silberstein S. Effect of OnabotulinumtoxinA Prevention on Comorbidities of Depression and Anxiety in Chronic Migraine: Analysis in Headache Day Frequency Responders vs Headache Day Frequency Non-Responders. American Headache Society – 60th Annual Scientific Meeting. 2018; San Francisco, CA.
  6. Blumenfeld A, Tepper S, Robbins L, Orejudos A, Manack Adams A, Buse D, Silberstein S. Effect of OnabotulinumtoxinA Prevention on Comorbidities of Depression and Anxiety in Chronic Migraine: Analysis in Headache Day Frequency Responders vs Headache Day Frequency Non-Responders. Headache Update 2018. 2018.
  7. Paul Winner, DO, FAAN, FAHS, Andrew M. Blumenfeld, MD, Eric J. Eross, DO, Amelia Orejudos, MSc, Aubrey Manack Adams, PhD, Mitchell F. Brin, MD, FAAN. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients: COMPEL Analysis by Treatment Cycle. Practicing Physician’s Approach to the Difficult Headache Patient – 31st Annual. 2018.
  8. Rothrock J, Lipton R, Silberstein S, Jo E, Zhao X, Manack Adams A, Blumenfeld A. A Multicenter, Prospective, Randomized, Open-Label Study to Compare the Efficacy, Safety, and Tolerability of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults with Chronic Migraine: The FORWARD Study. European Academy of Neurology – 4th Congress. 2018; Lisbon, Portugal.
  9. Rothrock J, Manack Adams A, Jo E, Zhao X, Blumenfeld A. A Multicenter, Prospective, Randomized, Open-Label Study to Compare the Efficacy, Safety, and Tolerability of OnabotulinumtoxinA and Topiramate for Headache Prophylaxis in Adults with Chronic Migraine: The FORWARD Study. Practicing Physician’s Approach to the Difficult Headache Patient – 31st Annual. 2018.
  10. Rothrock J, Manack Adams A, Lipton R, Silberstein S, Jo E, Zhao X, Blumenfeld A. A Multicenter, Prospective, Randomized, Open-Label Study to Compare the Efficacy, Safety, and Tolerability of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine: The FORWARD Study. American Headache Society – 60th Annual Scientific Meeting. 2018; San Francisco, CA.
  11. Tepper S, Wilson M, Orejudos A, Manack Adams A, Blumenfeld A. The Long-Term Efficacy and Safety of OnabotulinumtoxinA for the Prevention of Chronic Migraine in Patients with Medication Overuse: Results of the COMPEL Study. American Headache Society – 60th Annual Scientific Meeting. 2018; San Francisco, CA.
  12. Tepper S, Wilson M, Orejudos A, Manack Adams A, Blumenfeld A. The Long-Term Efficacy and Safety of OnabotulinumtoxinA for the Prevention of Chronic Migraine in Patients with Medication Overuse: Results of the COMPEL Study. European Academy of Neurology – 4th Congress. 2018; Lisbon, Portugal.
  13. Tepper S, Wilson M, Orejudos A, Manack Adams A, Blumenfeld A. The Long-Term Efficacy and Safety of OnabotulinumtoxinA for the Prevention of Chronic Migraine in Patients With Medication Overuse: Results of the COMPEL Study. Headache Update 2018. 2018.
  14. Tepper S, Wilson M, Rothrock J, Orejudos A, Manack Adams A, Blumenfeld A. Effect of OnabotulinumtoxinA Prevention on Comorbidities of Depression and Anxiety in Chronic Migraine: Analysis in Headache Day Frequency Responders vs Headache Day Frequency Nonresponders. European Headache Federation – 12th European Headache Federation Congress. 2018; Florence, Italy.
  15. Winner P, Blumenfeld A, Eross E, Orejudos A, Manack Adams A, Brin M. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients: COMPEL Analysis by Treatment Cycle. American Headache Society – 60th Annual Scientific Meeting. 2018; San Francisco, CA.

 

  1. Rothrock JF, Lipton RB, Young WB, Jo E, Manack Adams A, Blumenfeld AM. OnabotulinumtoxinA Is Safe and Effective in Patients Who Discontinue Topiramate: Results of the FORWARD Study. American Academy of Neurology – 71st Annual Meeting. 2019; Philadelphia, PA.

 

  1. Blumenfeld AM, Goadsby PJ, Dodick DW, Hutchinson S, Liu C, Finnegan M, Trugman JM, Szegedi A. Ubrogepant Is Effective for the Acute Treatment of Migraine in Patients With an Insufficient Response to Triptans. American Academy of Neurology – 71st Annual Meeting. 2019; Philadelphia, PA.

 

  1. Ailani J, Blumenfeld AM, Klein B, Finnegan M, Severt L, Liu CC, Trugman JM. An Optional Second Dose of Ubrogepant is Effective in Achieving 2-Hour Pain Freedom in the Acute Treatment of Migraine. American Headache Society – 61st Annual Scientific Meeting. 2019; Philadelphia, PA.

 

  1. Rothrock JF, Stark R, Sommer K, Blumenfeld AM. Healthcare Resource Utilization in Adult Patients Treated With OnabotulinumtoxinA for Chronic Migraine: Results From the COMPEL Study. American Headache Society – 61st Annual Scientific Meeting. 2019; Philadelphia, PA.

 

  1. Rothrock JF, Lipton RB, Young WB, Jo E, Manack Adams A, Blumenfeld AM. OnabotulinumtoxinA Is Safe and Effective in Patients Who Discontinue Topiramate: Results of the FORWARD Study. American Headache Society – 61st Annual Scientific Meeting. 2019; Philadelphia, PA.

 

  1. Hutchinson S, Silberstein SD, Blumenfeld AM, Lipton RB, Lu K, Yu SY, Severt L. Safety of Ubrogepant in Participants with Moderate to High Cardiovascular Risk. American Headache Society – 61st Annual Scientific Meeting. 2019; Philadelphia, PA.

 

  1. Blumenfeld AM, Goadsby PJ, Dodick DW, Hutchinson S, Liu C, Finnegan M, Trugman JM, Szegedi A. Ubrogepant is Effective for the Acute Treatment of Migraine in Patients for Whom Triptans are Ineffective. American Headache Society – 61st Annual Scientific Meeting. 2019; Philadelphia, PA.

 

  1. Rothrock JF, Lipton RB, Young WB, Jo E, Manack Adams A, Blumenfeld AM. OnabotulinumtoxinA Is Safe and Effective in Patients Who Discontinue Topiramate: Results of the FORWARD Study. Academy of Managed Care Pharmacy – 31st Annual Meeting & Expo. 2019; National Harbor, MD.

 

  1. Blumenfeld AM, Goadsby PJ, Dodick DW, Hutchinson S, Liu C, Finnegan M, Trugman JM, Szegedi A. Ubrogepant is Effective for the Acute Treatment of Migraine in Patients for Whom Triptans are Ineffective. Academy of Managed Care Pharmacy – 31st Annual Meeting & Expo. 2019; National Harbor, MD.

 

  1. Rothrock JF, Manack Adams A, Lipton RB, Silberstein SD, Jo E, Zhao X, Blumenfeld AM. Multicenter, Prospective, Randomized, Open-Label Study Comparing Efficacy, Safety, and Tolerability of OnabotulinumtoxinA and Topiramate in Chronic Migraine: The FORWARD Study. Canadian Pain Society – 40th Annual Conference. 2019; Toronto, ON.

 

  1. Rothrock JF, Lipton RB, Young WB, Jo E, Manack Adams A, Blumenfeld AM. OnabotulinumtoxinA Is Safe and Effective in Patients Who Discontinue Topiramate: Results of the FORWARD Study. Headache Update. 2019; Lake Buena Vista, FL.

 

  1. Blumenfeld AM, Dodick DW, Hutchinson S, Liu C, Finnegan M, Trugman JM, Szegedi A. Ubrogepant Is Effective For the Acute Treatment of Migraine in Patients with an Insufficient Reponse to Triptans. Headache Update. 2019; Lake Buena Vista, FL.

 

  1. Blumenfeld AM, Patel AT, Manack Adams A, Rothrock JF. OnabotulinumtoxinA Treatment Associated With Greater Tolerability and Improved Patient-Reported Functional Outcomes Than Topiramate: Results From the FORWARD Study. 32nd Annual Practicing Physician’s Approach to the Difficult Headache Patient. 2019; Carlsbad, CA.

 

  1. Rothrock JF, Lipton RB, Young WB, Jo E, Manack Adams A, Blumenfeld AM. OnabotulinumtoxinA Is Safe and Effective in Patients Who Discontinue Topiramate: Results of the FORWARD Study. European Academy of Neurology – 5th Congress. 2019; Oslo, Norway.

 

  1. Rothrock JF, Stark R, Sommer K, Blumenfeld AM. Healthcare Resource Utilization in Adult Patients Treated With OnabotulinumtoxinA for Chronic Migraine: Results From the COMPEL Study. European Headache Federation – 13th European Headache Federation Congress. 2019; Athens, Greece.

 

  1. Rothrock JF, Stark R, Sommer K, Blumenfeld AM. Healthcare Resource Utilization in Adult Patients Treated With OnabotulinumtoxinA for Chronic Migraine: Results From the COMPEL Study. International Headache Society – 19th International Headache Congress. 2019; Dublin, Ireland.

 

  1. Rothrock JF, Lipton RB, Young WB, Jo E, Manack Adams A, Blumenfeld AM. OnabotulinumtoxinA Is Safe and Effective in Patients Who Discontinue Topiramate: Results of the FORWARD Study. International Headache Society – 19th International Headache Congress. 2019; Dublin, Ireland.

 

  1. Hutchinson S, Silberstein SD, Blumenfeld AM, Lipton RB, Lu K, Yu SY, Severt L. Safety of Ubrogepant in Participants with Moderate to High Cardiovascular Risk. International Headache Society – 19th International Headache Congress. 2019; Dublin, Ireland.

 

  1. Blumenfeld AM, Goadsby PJ, Dodick DW, Hutchinson S, Liu C, Finnegan M, Trugman JM, Szegedi A. Ubrogepant is Effective for the Acute Treatment of Migraine in Patients with an Insufficient Response to Triptans. International Headache Society – 19th International Headache Congress. 2019; Dublin, Ireland.

 

  1. Winner PK, Blumenfeld AM, Eross EJ, Orejudos A, Manack Adams A, Brin MF. OnabotulinumtoxinA Is Well Tolerated In Chronic Migraine Patients Taking Oral Preventive Medications: Long-Term Compel Analysis By Treatment Cycle. The International Neurotoxin Association’s 4th international conference – TOXINS 2019: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins. 2019; Copenhagen, Denmark.

 

  1. Blumenfeld AM, Tepper SJ, Robbins LD, Orejudos AC, Manack Adams A, Buse DC, Silberstein SD. OnabotulinumtoxinA Treatment For Chronic Migraine Reduces Depression And Anxiety In Headache Day Frequency Responders And Nonresponders. The International Neurotoxin Association’s 4th international conference – TOXINS 2019: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins. 2019; Copenhagen, Denmark.

 

  1. Blumenfeld AM, Goadsby PJ, Dodick DW, Hutchinson S, Liu C, Finnegan M, Trugman JM, Szegedi A. Ubrogepant is Effective for the Acute Treatment of Migraine in Patients with an Insufficient Response to Triptans. PAINWeek 2019. 2019; Las Vegas, NV.

 

  1. Hutchinson S, Silberstein SD, Blumenfeld AM, Lipton RB, Lu K, Yu SY, Severt L. Safety and Efficacy of Ubrogepant in Participants With Moderate to High Cardiovascular Risk. Headache Cooperative of the Pacific – 13th Annual Winter Conference. 2020; Ojai, CA.

 

  1. Blumenfeld AM, Goadsby PJ, Dodick DW, Hutchinson S, Liu C, Finnegan M, Trugman JM, Szegedi A. Ubrogepant is Effective for the Acute Treatment of Migraine in Patients with an Insufficient Response to Triptans. Headache Cooperative of the Pacific – 13th Annual Winter Conference. 2020; Ojai, CA.

 

  1. Hutchinson S, Silberstein SD, Blumenfeld AM, Lipton RB, Lu K, Yu SY, Severt L. Safety and Efficacy of Ubrogepant in Participants With Moderate to High Cardiovascular Risk. Diamond Headache Clinic Research and Educational Foundation – 2020 Annual Research Summit. 2020; San Diego, CA.

 

  1. Blumenfeld AM, Diener HC, Lipton RB, Dodick DW, Degryse R, Manack Adams A, Silberstein SD. Clinically Meaningful Benefits of OnabotulinumtoxinA Beyond Headache Days in Chronic Migraine: Analysis of the COMPEL and Pooled PREEMPT Studies. Diamond Headache Clinic Research and Educational Foundation – 2020 Annual Research Summit. 2020; San Diego, CA.

 

  1. Severt L, Silberstein SD, Blumenfeld AM, Lipton RB, Lu K, Yu SY, Hutchinson S. Safety and Efficacy of Ubrogepant in Participants With Moderate to High Cardiovascular Risk. American Academy of Neurology 2020 – 72nd Annual Meeting. 2020; Virtual.

 

  1. Rothrock JF, Stark R, Sommer K, Blumenfeld AM. Healthcare Resource Utilization in Adult Patients Treated With OnabotulinumtoxinA for Chronic Migraine: Results From the COMPEL Study. American Academy of Neurology 2020 – 72nd Annual Meeting. 2020; Virtual.

 

  1. Blumenfeld AM, Diener HC, Lipton RB, Dodick DW, Degryse R, Manack Adams A, Silberstein SD. Clinically Meaningful Benefits of OnabotulinumtoxinA Beyond Headache Days in Chronic Migraine: Analysis of the COMPEL and Pooled PREEMPT Studies. American Academy of Neurology 2020 – 72nd Annual Meeting. 2020; Virtual.

 

  1. Rothrock JF, Luo L, Eross E, Sommer K, Blumenfeld AM. Responder Rates to OnabotulinumtoxinA in Patients With Chronic Migraine: A Post Hoc Analysis of the COMPEL Study. American Academy of Neurology 2020 – 72nd Annual Meeting. 2020; Virtual.

 

  1. Blumenfeld AM, Luo L, Yedigarova L, Lipton RB. Benefits of Long-Term OnabotulinumtoxinA Treatment in Chronic Migraine: Results from the COMPEL Study. American Academy of Neurology 2020 – 72nd Annual Meeting. 2020; Virtual.

 

  1. Blumenfeld AM, Knievel K, Manack Adams A, Severt L, Butler M, Lai J, Dodick DW. Efficacy and Safety of Ubrogepant in Participants Taking Concomitant Preventive Medication. American Academy of Neurology 2020 – 72nd Annual Meeting. 2020; Virtual.

 

  1. Ailani J, Blumenfeld AM, Klein B, Finnegan M, Severt L, Liu CC, Trugman JM. An Optional Second Dose of Ubrogepant is Effective in Achieving 2-Hour Pain Freedom in the Acute Treatment of Migraine. American Academy of Neurology 2020 – 72nd Annual Meeting. 2020; Virtual.

 

  1. Blumenfeld AM, Knievel K, Manack Adams A, Severt L, Butler M, Lai H, Dodick DW. Efficacy and Safety of Ubrogepant in Participants Taking Concomitant Preventive Medication. American Headache Society – 62nd Annual Scientific Meeting. 2020; Virtual.

 

  1. Blumenfeld AM, Luo L, Yedigarova L, Lipton RB. Benefits of Long-Term OnabotulinumtoxinA Treatment in Chronic Migraine: Results from the COMPEL Study. American Headache Society – 62nd Annual Scientific Meeting. 2020; Virtual.

 

  1. Rothrock JF, Luo L, Eross E, Sommer K, Blumenfeld AM. Responder Rates to OnabotulinumtoxinA in Patients With Chronic Migraine: A Post Hoc Analysis of the COMPEL Study. American Headache Society – 62nd Annual Scientific Meeting. 2020; Virtual.

 

  1. Blumenfeld AM, Luo L, Yedigarova L, Lipton RB. Benefits of Long-Term OnabotulinumtoxinA Treatment in Chronic Migraine: Results from the COMPEL Study. EHF (2020) European Headache Federation – 14th European Headache Federation Congress. 2020; Virtual.

 

  1. Jakate A, Blumenfeld AM, Boinpally R, Butler M, Borbridge L, Contreras-De Lama J, McGeeney D, Periclou A, Lipton RB. Pharmacokinetics, Safety, and Tolerability of Ubrogepant for the Acute Treatment of Migraine Following Coadministration With Preventive Monoclonal Antibody Treatment. MTIS (2020) Migraine Trust International Symposium – 2020 Virtual Symposium.

 

  1. Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L, Manack Adams A. Real-World Evidence for Control of Patients With Chronic Migraine Who Received CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment. MTIS (2020) Migraine Trust International Symposium – 2020 Virtual Symposium.

 

  1. Blumenfeld AM, Knievel K, Manack Adams A, Severt L, Butler M, Lai H, Dodick DW. Efficacy and Safety of Ubrogepant in Participants Taking Concomitant Preventive Medication. MTIS (2020) Migraine Trust International Symposium – 2020 Virtual Symposium.

 

  1. Blumenfeld AM, Diener HC, Lipton RB, Dodick DW, Degryse R, Manack Adams A, Sommer K, Silberstein SD. OnabotA for CM: Benefits Beyond Headache-Day Reduction. ABN (2020) Association of British Neurologists – 2020 Annual Meeting.

 

  1. Blumenfeld AM, Knievel K, Manack Adams A, Severt L, Butler M, Lai H, Dodick DW. Efficacy and Safety of Ubrogepant in Participants Taking Concomitant Preventive Medication. HCOP (2021) Headache Cooperative of the Pacific – 14th Annual Winter Conference; Virtual.

 

  1. Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Yedigarova L, Manack Adams A. Real-World Evidence for Control of Patients With Chronic Migraine Who Received Calcitonin Gene‒Related Peptide (CGRP) Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment. HCOP (2021) Headache Cooperative of the Pacific – 14th Annual Winter Conference; Virtual.

 

  1. Blumenfeld AM, Frishberg BM, Schim JD, Hughes O, Manack Adams A. Real-World Evidence for Control of Chronic Migraine (CM) in Patients Meeting American Headache Society (AHS) Criteria Who Received Calcitonin Gene‒Related Peptide Monoclonal Antibody (CGRPmAb) Therapy Added to OnabotulinumtoxinA Treatment. DHCREF (2021) Diamond Headache Clinic Research and Educational Foundation – 2021 Annual Research Summit; Virtual.

 

  1. Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes J, Gandhi P, Dodick DW. Effects of Atogepant as Evaluated by the Activity Impairment in Migraine-Diary (AIM-D) and Headache Impact Test (HIT-6) in a 12-Week, Double-blind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine. AMCP (2021) Academy of Managed Care Pharmacy 2021 – 33rd Annual Meeting & Expo; Virtual.

 

  1. Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes J, Gandhi P, Dodick DW. Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine. AMCP (2021) Academy of Managed Care Pharmacy 2021 – 33rd Annual Meeting & Expo; Virtual.

 

  1. Blumenfeld AM, Frishberg BM, Schim JD, Hughes O, Yedigarova L, Manack Adams A. Real-World Evidence for Control of Patients With Chronic Migraine Who Received Calcitonin Gene‒Related Peptide (CGRP) Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment. AMCP (2021) Academy of Managed Care Pharmacy 2021 – 33rd Annual Meeting & Expo; Virtual.

 

  1. Jakate A, Blumenfeld AM, Boinpally R, Butler M, Borbridge L, Contreras-De Lama J, McGeeney D, Periclou A, Lipton RB. Pharmacokinetics, Safety, and Tolerability of Ubrogepant for the Acute Treatment of Migraine Following Coadministration With Preventive Monoclonal Antibody Treatment. AAN (2021) American Academy of Neurology 2021 – 73rd Annual Meeting; Virtual.

 

  1. Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes J, Gandhi P, Dodick DW. Atogepant Improved Patient-Reported Outcome (PRO) Measures of Activity Impairment in Migraine-Diary and Headache Impact Test in a 12-Week, Doubleblind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine. AAN (2021) American Academy of Neurology 2021 – 73rd Annual Meeting; Virtual.

 

  1. Dodick DW, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes J, Gandhi P, Lipton RB. Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine. AAN (2021) American Academy of Neurology 2021 – 73rd Annual Meeting; Virtual.

 

  1. Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Yedigarova L, Manack Adams A. Real-World Evidence for Control of Chronic Migraine (CM) in Patients Meeting American Headache Society (AHS) Criteria Who Received Calcitonin Gene‒Related Peptide Monoclonal Antibody (CGRPmAb) Therapy Added to OnabotulinumtoxinA Treatment. AAN (2021) American Academy of Neurology 2021 – 73rd Annual Meeting; Virtual.

 

  1. Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Yedigarova L, Manack Adams A. Real-World Evidence for Control of Patients With Chronic Migraine Who Received Calcitonin Gene‒Related Peptide (CGRP) Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment. AAN (2021) American Academy of Neurology 2021 – 73rd Annual Meeting; Virtual.

 

  1. Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes J, Gandhi P, Dodick DW. Effects of Atogepant as Evaluated by the Activity Impairment in Migraine-Diary (AIM-D) and Headache Impact Test (HIT-6) in a 12-Week, Double-blind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine. AHS (2021) American Headache Society – 63rd Annual Scientific Meeting; Virtual.

 

  1. Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes J, Gandhi P, Dodick DW. Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine. AHS (2021) American Headache Society – 63rd Annual Scientific Meeting; Virtual.

 

  1. Blumenfeld AM, Frishberg BM, Schim JD, Hughes O, Yedigarova L, Manack Adams A. Real-World Evidence for Control of Chronic Migraine in Patients Meeting American Headache Society Criteria Who Received Calcitonin Gene‒Related Peptide Monoclonal Antibody Therapy Added to OnabotulinumtoxinA. AHS (2021) American Headache Society – 63rd Annual Scientific Meeting; Virtual.

 

  1. Blumenfeld AM, Frishberg BM, Schim JD, Hughes O, Manack Adams A. Real-World Evidence for Control of Patients With Chronic Migraine Who Received Calcitonin Gene‒Related Peptide Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment. AHS (2021) American Headache Society – 63rd Annual Scientific Meeting; Virtual.

 

  1. Ashina M, Tepper S, Reuter U, Blumenfeld A, Hutchinson S, Xia J, Miceli R, Severt L, Finnegan M, Trugman J. Atogepant 60 mg Once-Daily Shows Efficacy for the Preventive Treatment of Migraine: Results From a 52-Week Open-Label Extension Trial. AHS (2021) American Headache Society – 63rd Annual Scientific Meeting; Virtual.

 

  1. Lipton RB, Pozo Rosich P, Blumenfeld AM, Dodick D, McAllister, Li Y, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman J . Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days. AHS (2021) American Headache Society – 63rd Annual Scientific Meeting; Virtual.

 

  1. Ashina M, Tepper A, Reuter U, Blumenfeld A, Hutchinson S, Xia J, Miceli R, Severt L, Finnegan M, Trugman J. Long-term Safety and Tolerability of Atogepant Following Once Daily Dosing Over 1 Year for the Preventive Treatment of Migraine. AHS (2021) American Headache Society – 63rd Annual Scientific Meeting; Virtual.

 

  1. Blumenfeld AM, Frishberg BM, Schim JD, Hughes O, Sommer K, Manack Adams A. Real-world evidence for chronic migraine control in patients receiving treatment with CGRP mAbs and onabotulinumtoxinA. AANP (2021) American Association of Nurse Practitioners – 2021 National Conference; Virtual.

 

  1. Ashina M, Tepper S, Reuter U, Blumenfeld A, Hutchinson S, Xia J, Miceli R, Severt L, Finnegan M, Trugman J. Atogepant 60 mg Once-Daily Shows Efficacy for the Preventive Treatment of Migraine: Results From a 52-Week Open-label Extension Trial. AANP (2021) American Association of Nurse Practitioners – 2021 National Conference; Virtual.

 

  1. Lipton RB, Pozo Rosich P, Blumenfeld AM, Dodick D, McAllister, Li Y, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman J. Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days. AANP (2021) American Association of Nurse Practitioners – 2021 National Conference; Virtual.

 

  1. Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes J, Gandhi P, Dodick DW. Atogepant Improved Measures of Functioning Using AIM-D and HIT-6 in a 12-Week Phase 3 Trial for Migraine Prevention. EAN (2021) European Academy of Neurology – 7th Congress; Virtual.

 

  1. Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes J, Gandhi P, Dodick DW. Atogepant Improved Patient Functioning Using MSQ v2.1 in a 12-Week Phase 3 (ADVANCE) Trial for Migraine Prevention. EAN (2021) European Academy of Neurology – 7th Congress; Virtual.

 

  1. Blumenfeld AM, Frishberg BM, Schim JD, Hughes O, Sommer K, Manack Adams A. Real-world evidence for chronic migraine control in patients receiving treatment with CGRP mAbs and onabotulinumtoxinA. EAN (2021) European Academy of Neurology – 7th Congress; Virtual.

 

  1. Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes J, Gandhi P, Dodick DW. Effects of Atogepant as Evaluated by the Activity Impairment in Migraine-Diary (AIM-D) and Headache Impact Test (HIT-6) in a 12-Week, Double-blind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine. DHCREF (2021) Headache Update 2021.

 

  1. Lipton RB, Pozo Rosich P, Blumenfeld AM, Dodick DW, McAllister P, Li Y, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman JM. Oral daily Atogepant for the preventive treatment of migraine increases responder rates for reduction in mean monthly migraine days. DHCREF (2021) Headache Update 2021.

 

  1. Ashina M, Tepper A, Reuter U, Blumenfeld AM, Hutchinson S, Xia J, Miceli R, Severt L, Finnegan M, Trugman JM. Long-term safety and tolerability of Atogepant 60 mg following once daily dosing over 1 year for the preventive treatment of migraine. DHCREF (2021) Headache Update 2021.

 

  1. Blumenfeld AM, Frishberg BM, Schim JD, Hughes O, Manack Adams A. Real-World Evidence for Control of Patients With Chronic Migraine Who Received Calcitonin Gene‒Related Peptide (CGRP) Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment. DHCREF (2021) Headache Update 2021.

 

  1. Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes J, Gandhi P, Dodick DW. Effects of Atogepant as Evaluated by the Activity Impairment in Migraine-Diary (AIM-D) and Headache Impact Test (HIT-6) in a 12-Week, Double-blind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine. EHF (2021) European Headache Federation – 15th European Headache Federation Congress; Virtual.

 

  1. Blumenfeld AM, Frishberg BM, Schim JD, Hughes O, Manack Adams A. Real-World Evidence for Control of Patients With Chronic Migraine Who Received Calcitonin Gene‒Related Peptide Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment. EHF (2021) European Headache Federation – 15th European Headache Federation Congress; Virtual.

 

  1. Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes J, Gandhi P, Dodick DW. Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine. EHF (2021) European Headache Federation – 15th European Headache Federation Congress; Virtual.

 

  1. Lipton RB, Pozo Rosich P, Blumenfeld AM, Dodick D, McAllister, Li Y, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman J. Oral Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days. EHF (2021) European Headache Federation – 15th European Headache Federation Congress; Virtual.

Medical journal reviewer

  • Headache
  • Cephalalgia
  • Neurology (US and European)
  • Lancet
  • Pain and Therapy (Editorial Board member )

US and European PATENTS

25 issued patents:

  1. 8,617,572 Botulinum toxin treatments of depression
  2. 8,617,571 Suture line administration technique using botulinum toxin
  3. 8,609,113 Botulinum toxin treatments of depression
  4. 8,609,112 Botulinum toxin treatments of depression
  5. 8,603,983 Targeted delivery of botulinum toxin for the treatment and prevention of   trigeminal autonomic cephalgias, migraine and vascular conditions
  6. 8,530,425 Targeted delivery of botulinum toxin to the sphenopalatine ganglion
  7. 8,388,952 Botulinum toxin compositions and methods
  8. 8,383,103 Botulinum toxin compositions and methods
  9. 8,241,641 Targeted delivery of botulinum toxin for the treatment and prevention of    trigeminal autonomic cephalgias, migraine and vascular conditions
  10.   7,981,433 Targeted delivery of botulinum toxin to the sphenopalatine ganglion
  11.   7,749,515 Targeted delivery of botulinum toxin to the sphenopalatine ganglion
  12.   7,655,244 Targeted delivery of botulinum toxin for the treatment and prevention of   trigeminal autonomic cephalgias, migraine and vascular conditions.
  13. Use of Botulinum toxins in the treatment of neuro-psychiatric conditions. Granted in: AU, CH, CN, DE, DK, ES, FR, UK, IE, IT, MX, NL, SE.  EP 1677823
  14. US 11,077,174 B2, Treatment of psychological trauma
  15. US 10,874,722 B2, Suture line administration technique using botulinum toxins
  16. US 10,729,751 B2, Injection paradigm for administration of botulinum toxins.
  17. EP 2,627,350 A1, Targeted delivery of exocytosis modulators to the sphenopalatine ganglion for treatment of headache disorders
  18. EP 2,358,376 A1,
  19. US 9 ,827,297 B2 line administration technique using botulinum toxins
  20. US 8,846,622 B2 Targeted delivery of botulinum toxin to the sphenopalatine ganglion
  21. US 9,238,061 B2 Botulinum toxin treatment of anxiety and bipolar disorders
  22. US 10,064,921 Botulinum toxin treatments of neurological and neuropsychiatric disorders
  23. US 8,697,066 Botulinum toxin compositions and methods
  24. US 10,220,079 Suture line administration technique using botulinum toxins
  25. US 10,111,938 Injection paradigm for administration of botulinum toxins